REFERENCES 1. Abrami, L., S. Liu, P. Cosson, S. H. Leppla, and F. G. van der Goot. 2003. Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrin-dependent process. J. Cell Biol. 160:3321-3328. 2. Acheson, D. W. K., and G. T. Keusch. 1999. The family of Shiga toxins, p. 229-242. In J. E. Alouf and J. H. Freer (ed.), The comprehensive sourcebook of bacterial protein toxins. Academic Press, Inc., New York, N.Y. 3. Agrawal, A., J. Lingappa, S. H. Leppla, S. Agrawal, A. Jabbar, C. Quinn, and B. Pulendran. 2003. Impairment of dendritic cells and adaptive immunity by anthrax lethal toxin. Nature 424:329-334. [PubMed]. 4. Ahuja, N., P. Kumar, S. Alam, M. Gupta, and R. Bhatnagar. 2003. Deletion mutants of protective antigen that inhibit anthrax toxin both in vitro and in vivo. Biochem. Biophys. Res. Commun. 307:446-450. [PubMed]. 5. Ahuja, N., P. Kumar, and R. Bhatnagar. 2001. Hydrophobic residues Phe552, Phe554, Ile562, Leu566, and Ile574 are required for oligomerization of anthrax protective antigen. Biochem. Biophys. Res. Commun. 287:542-549. [PubMed]. 6. Aktories, K., T. Ankenbauer, B. Schering, and K. H. Jakobs. 1986. ADP-ribosylation of platelet actin by botulinum C2 toxin. Eur. J. Biochem. 161:155-162. [PubMed]. 7. Aktories, K., M. Bärmann, I. Ohishi, S. Tsuyama, K. H. Jakobs, and E. Habermann. 1986. Botulinum C2 toxin ADP-ribosylates actin. Nature 322:390-392. [PubMed]. 8. Aktories, K., U. Braun, S. Rösener, I. Just, and A. Hall. 1989. The rho gene product expressed in E. coli is a substrate of botulinum ADP-ribosyltransferase C3. Biochem. Biophys. Res. Commun. 158:209-213. [PubMed]. 9. Aktories, K., and I. Just. 1990. Botulinum C2 toxin, p. 79-95. In J. Moss and M. Vaughan (ed.), ADP-ribosylating toxins and G-proteins. American Society for Microbiology, Washington, D.C. 10. Aktories, K., and G. Koch. 1995. Modification of actin and of Rho proteins by clostridial ADP-ribosylating toxins, p. 491-520. In B. Iglewski, J. Moss, A. T. Tu, and M. Vaughan (ed.), Microbial toxins and virulence factors in disease. Marcel Dekker, Inc., New York, N.Y. 11. Aktories, K., C. Mohr, and G. Koch. 1992. Clostridium botulinum C3 ADP-ribosyltransferase. Curr. Top. Microbiol. Immunol. 175:115-131. [PubMed]. 12. Aktories, K., K.-H. Reuner, P. Presek, and M. Barmann. 1989. Botulinum C2 toxin treatment increases the G-actin pool in intact chicken cells: a model for the cytopathic action of actin-ADP-ribosylating toxins. Toxicon 27:989-993. [PubMed]. 13. Aktories, K., and A. Wegner. 1989. ADP-ribosylation of actin by clostridial toxins. J. Cell Biol. 109:1385-1387. [PubMed]. 14. Aktories, K., U. Weller, and G. S. Chhatwal. 1987. Clostridium botulinum type C produces a novel ADP-ribosyltransferase distinct from botulinum C2 toxin. FEBS Lett. 212:109-113. [PubMed]. 15. Aktories, K., M. Wille, and I. Just. 1992. Clostridial actin-ADP-ribosylating toxins. Curr. Top. Microbiol. Immunol. 175:97-113. [PubMed]. 16. Al-Mohanna, F. A., I. Ohishi, and M. B. Hallett. 1987. Botulinum C2 toxin potentiates activation of the neutrophil oxidase. Further evidence of a role for actin polymerization. FEBS Lett. 219:40-44. [PubMed]. 17. Altboum, Z., Y. Gozes, A. Barnea, A. Pass, M. White, and D. Kobiler. 2002. Postexposure prophylaxis against anthrax: evaluation of various treatment regimens in intranasally infected guinea pigs. Infect. Immun. 70:6231-6241. [PubMed]. 18. Anne, C., F. Cornille, C. Lenoir, and B. P. Roques. 2001. High-throughput fluorogenic assay for determination of botulinum type B neurotoxin protease activity. Anal. Biochem. 291:253-261. [PubMed]. 19. Arora, N. 1997. Site directed mutagenesis of histidine residues in anthrax toxin lethal factor binding domain reduces toxicity. Mol. Cell. Biochem. 177:7-14. [PubMed]. 20. Arora, N., K. R. Klimpel, Y. Singh, and S. H. Leppla. 1992. Fusions of anthrax toxin lethal factor to the ADP-ribosylation domain of Pseudomonas exotoxin A are potent cytotoxins which are translocated to the cytosol of mammalian cells. J. Biol. Chem. 267:15542-15548. [PubMed]. 21. Arora, N., and S. H. Leppla. 1993. Residues 1-254 of anthrax toxin lethal factor are sufficient to cause cellular uptake of fused polypeptides. J. Biol. Chem. 268:3334-3341. [PubMed]. 22. Arora, N., and S. H. Leppla. 1994. Fusions of anthrax toxin lethal factor with shiga toxin and diphtheria toxin enzymatic domains are toxic to mammalian cells. Infect. Immun. 62:4955-4961. [PubMed]. 23. Arora, N., L. C. Williamson, S. H. Leppla, and J. L. Halpern. 1994. Cytotoxic effects of a chimeric protein consisting of tetanus toxin light chain and anthrax toxin lethal factor in non-neuronal cells. J. Biol. Chem. 269:26165-26171. [PubMed]. 24. Azhar, A. M., S. Singh, P. Anand Kumar, and R. Bhatnagar. 2002. Expression of protective antigen in transgenic plants: a step towards edible vaccine against anthrax. Biochem. Biophys. Res. Commun. 299:345-351. [PubMed]. 25. Babudieri, S., S. P. Borriello, A. Pantosti, I. Luzzi, G. P. Testore, and G. Panichi. 1986. Diarrhoea associated with toxigenic Clostridium spiroforme. J. Infect. 12:278-279. [PubMed]. 26. Bachmeyer, C., R. Benz, H. Barth, K. Aktories, M. Gibert, and M. Popoff. 2001. Interaction of Clostridium botulinum C2-toxin with lipid bilayer membranes and vero cells: inhibition of channel function by chloroquine and related compounds in vitro and intoxication in vivo. FASEB J. 15:1658-1660. [PubMed]. 26a. Bachmeyer, C., F. Orlik, H. Barth, K. Aktories, and R. Benz. 2003. Mechanism of C2- toxin inhibition by fluphenazine and related compounds: investigation of their binding kinetics to the C2II-channel using the current noise analysis. J. Mol. Biol. 333:527-540. [PubMed]. 27. Ballard, J. D., R. J. Collier, and M. N. Starnbach. 1996. Anthrax toxin-mediated delivery of a cytotoxic T-cell epitope in vivo. Proc. Natl. Acad. Sci. USA 93:12531-12534. [PubMed]. 28. Ballard, J. D., R. J. Collier, and M. N. Starnbach. 1998. Anthrax toxin as a molecular tool for stimulation of cytotoxic T lymphocytes: disulfide-linked epitopes, multiple injections, and role of CD4 + cells. Infect. Immun. 66:4696-4699. [PubMed]. 29. Ballard, J. D., A. M. Doling, K. Beauregard, R. J. Collier, and M. N. Starnbach. 1998. Anthrax toxin-mediated delivery in vivo and in vitro of a cytotoxic T-lymphocyte epitope from ovalbumin. Infect. Immun. 66:615-619. [PubMed]. 30. Ballweber, E., M. Galla, K. Aktories, S. Yeoh, A. G. Weeds, and H. G. Mannherz. 2001. Interaction of ADP-ribosylated actin with actin binding proteins. FEBS Lett. 508:131-135. [PubMed]. 31. Barth, H., D. Blöcker, and K. Aktories. 2002. The uptake machinery of clostridial actin ADP-ribosylating toxins—a cell delivery system for fusion proteins and polypeptide drugs. Naunyn-Schmiedeberg's Arch. Pharmacol. 366:501-512. [PubMed]. 32. Barth, H., D. Blöcker, J. Behlke, W. Bergsma-Schutter, A. Brisson, R. Benz, and K. Aktories. 2000. Cellular uptake of Clostridium botulinum C2 toxin requires oligomerization and acidification. J. Biol. Chem. 275:18704-18711. [PubMed]. 33. Barth, H., F. Hofmann, C. Olenik, I. Just, and K. Aktories. 1998. The N-terminal part of the enzyme component (C2I) of the binary Clostridium botulinum C2 toxin interacts with the binding component C2II and functions as a carrier system for a Rho ADP-ribosylating C3-like fusion toxin. Infect Immun. 66:1364-1369. [PubMed]. 34. Barth, H., M. Klingler, K. Aktories, and V. Kinzel. 1999. Clostridium botulinum C2 toxin delays entry into mitosis and activation of p34 cdc2 kinase and cdc25-C phosphatase in HeLa cells. Infect. Immun. 67:5083-5090. [PubMed]. 35. Barth, H., C. Olenik, P. Sehr, G. Schmidt, K. Aktories, and D. K. Meyer. 1999. Neosynthesis and activation of Rho by Escherichia coli cytotoxic necrotizing factor (CNF1) reverse cytopathic effects of ADP-ribosylated Rho. J. Biol. Chem. 274:27407-27414. [PubMed]. 36. Barth, H., J. C. Preiss, F. Hofmann, and K. Aktories. 1998. Characterization of the catalytic site of the ADP-ribosyltransferase Clostridium botulinum C2 toxin by site-directed mutagenesis. J. Biol. Chem. 273:29506-29511. [PubMed]. 37. Barth, H., R. Roebling, M. Fritz, and K. Aktories. 2002. The binary Clostridium botulinum C2 toxin as a protein delivery system: identification of the minimal protein region necessary for interaction of toxin components. J. Biol. Chem. 277:5074-5081. [PubMed]. 38. Bartlett, J. G., T. V. Inglesby Jr., and L. Borio. 2002. Management of anthrax. Clin. Infect. Dis. 35:851-858. [PubMed]. 39. Batra, S., P. Gupta, V. Chauhan, A. Singh, and R. Bhatnagar. 2001. Trp 346 and Leu 352 residues in protective antigen are required for the expression of anthrax lethal toxin activity. Biochem. Biophys. Res. Commun. 281:186-192. [PubMed]. 40. Beauregard, K. E., R. J. Collier, and J. A. Swanson. 2000. Proteolytic activation of receptor-bound anthrax protective antigen on macrophages promotes its internalization. Cell. Microbiol. 2:251-258. [PubMed]. 41. Beauregard, K. E., S. Wimer-Mackin, R. J. Collier, and W. I. Lencer. 1999. Anthrax toxin entry into polarized epithelial cells. Infect. Immun. 67:3026-3030. [PubMed]. 42. Beedham, R. J., P. C. Turnbull, and E. D. Williamson. 2001. Passive transfer of protection against Bacillus anthracis infection in a murine model. Vaccine 19:4409-4416. [PubMed]. 43. Benson, E. L., P. D. Huynh, A. Finkelstein, and R. J. Collier. 1998. Identification of residues lining the anthrax protective antigen channel. Biochemistry 37:3941-3948. [PubMed]. 44. Bershadsky, A. D., U. Glück, O. N. Denisenko, T. V. Sklyarova, I. Spector, and A. Ben- Ze'ev. 1995. The state of actin assembly regulates actin and vinculin expression by a feedback loop. J. Cell Sci. 108:1183-1193. [PubMed]. 45. Billington, S. J., E. U. Wieckowski, M. R. Sarker, D. Bueschel, J. G. Songer, and B. A. McClane. 1998. Clostridium perfringens type E animal enteritis isolates with highly conserved, silent enterotoxin gene sequences. Infect. Immun. 66:4531-4536. [PubMed]. 46. Blaustein, R. O., T. M. Koehler, R. J. Collier, and A. Finkelstein. 1989. Anthrax toxin: channel-forming activity of protective antigen in planar phospholipid bilayers. Proc. Natl. Acad. Sci. USA 86:2209-2213. [PubMed]. 47. Blöcker, D., C. Bachmeyer, R. Benz, K. Aktories, and H. Barth. 2003. Channel formation by the binding component of Clostridium botulinum C2 toxin: glutamate 307 of C2II affects channel properties in vitro and pH-dependent C2I translocation in vivo. Biochemistry 42:5368-5377. [PubMed]. 48. Blöcker, D., H. Barth, E. Maier, R. Benz, J. T. Barbieri, and K. Aktories. 2000. The C terminus of component C2II of Clostridium botulinum C2 toxin is essential for receptor binding. Infect. Immun. 68:4566-4573. [PubMed]. 49. Blöcker, D., J. Behlke, K. Aktories, and H. Barth. 2001. Cellular uptake of the binary Clostridium perfringens iota-toxin. Infect. Immun. 69:2980-2987. [PubMed]. 50. Blöcker, D., K. Pohlmann, G. Haug, C. Bachmeyer, R. Benz, K. Aktories, and H. Barth. 2003. Clostridium botulinum C2 toxin: low pH-induced pore formation is required for translocation of the enzyme component C2I into the cytosol of host cells. J. Biol. Chem. 278:37360-37367. [PubMed]. 51. Bohannon, J. 2003. Anthrax. From bioweapons backwater to main attraction. Science 300:414-415. [PubMed]. 52. Borriello, S., and R. Carman. 1983. Association of iota-like toxin and Clostridium spiroforme with both spontaneous and antibiotic-associated diarrhea and colitis in rabbits. J. Clin. Microbiol. 17:414-418. [PubMed]. 53. Borriello, S., H. A. Davies, and R. J. Carman. 1986. Cellular morphology of Clostridium spiroforme. Vet. Microbiol. 11:191-195. [PubMed]. 54. Bosworth, T. 1940. On a new type of toxin produced by Clostridium welchii. J. Comp. Pathol. 53:245-255. 55. Bottinger, H., K. H. Reuner, and K. Aktories. 1987. Inhibition of histamine release from rat mast cells by botulinum C2 toxin. Int. Arch. Allergy Appl. Immunol. 84:380-384. [PubMed]. 56. Bourgogne, A., M. Drysdale, S. G. Hilsenbeck, S. N. Peterson, and T. M. Koehler. 2003. Global effects of virulence gene regulators in a Bacillus anthracis strain with both virulence plasmids. Infect. Immun. 71:2736-2743. [PubMed]. 57. Bourne, H. R., L. M. Lichtenstein, K. L. Melmon, C. S. Henney, Y. Weinstein, and G. M. Shearer. 1974. Modulation of inflammation and immunity by cyclic AMP. Science 184:19-24. [PubMed]. 58. Boyaka, P. N., A. Tafaro, R. Fischer, S. H. Leppla, K. Fujihashi, and J. R. McGhee. 2003. Effective mucosal immunity to anthrax: neutralizing antibodies and Th cell responses following nasal immunization with protective antigen. J. Immunol. 170:5636-5643. [PubMed]. 59. Brachman, P., S. H. Gold, S. A. Plotkin, F. R. Fekety, M. Werrin, and N. R. Ingraham. 1962. Field evaluation of a human anthrax vaccine. Am. J. Public Health 52:632-645. 60. Bradley, K. A., J. Mogridge, M. Mourez, R. J. Collier, and J. A. Young. 2001. Identification of the cellular receptor for anthrax toxin. Nature 414:225-229. [PubMed]. 61. Bradley, K. A., J. Mogridge, G. J. Rainey, S. Batty, and J. A. Young. 2003. Binding of anthrax toxin to its receptor is similar to alpha integrin-ligand interactions. J. Biol. Chem. 278:49342-49347. [PubMed]. 62. Bragg, T. S., and D. L. Robertson. 1989. Nucleotide sequence and analysis of the lethal factor gene ( lef) from Bacillus anthracis. Gene 81:45-54. [PubMed]. 63. Braun, M., C. Herholz, R. Straub, B. Choisat, J. Frey, J. Nicolet, and P. Kuhnert. 2000. Detection of the ADP-ribosyltransferase toxin gene ( cdtA) and its activity in Clostridium difficile isolates from equidae. FEMS Microbiol. Lett. 184:29-33. [PubMed]. 63a. Brossier, F., M. Levy, and M. Mock. 2002. Anthrax spores make an essential contribution to vaccine efficacy. Infect. Immun. 70:661-664. [PubMed]. 64. Brossier, F., J. C. Sirard, C. Guidi-Rontani, E. Duflot, and M. Mock. 1999. Functional analysis of the carboxy-terminal domain of Bacillus anthracis protective antigen. Infect. Immun. 67:964-967. [PubMed]. 65. Brossier, F., M. Weber-Levy, M. Mock, and J.-C. Sirard. 2000. Protective antigen-mediated antibody response against a heterologous protein produced in vivo by Bacillus anthracis. Infect. Immun. 68:5731-5734. [PubMed]. 66. Brossier, F., M. Weber-Levy, M. Mock, and J.-C. Sirard. 2000. Role of toxin functional domains in anthrax pathogenesis. Infect. Immun. 68:1781-1786. [PubMed]. 67. Bryskier, A. 2002. Bacillus anthracis and antibacterial agents. Clin. Microbiol. Infect. 8:467-478. [PubMed]. 68. Butt, M. T., R. E. Papendick, L. G. Carbone, and F. W. Quimby. 1994. A cytotoxicity assay for Clostridium spiroforme enterotoxin in cecal fluid of rabbits. Lab. Anim. Sci. 44:52-54. [PubMed]. 69. Cao, H., D. Agrawal, N. Kushner, N. Touzjian, M. Essex, and Y. Lu. 2002. Delivery of exogenous protein antigens to major histocompatibility complex class I pathway in cytosol. J. Infect. Dis. 185:244-251. [PubMed]. 70. Carman, R. J., and S. P. Borriello. 1982. Observations on an association between Clostridium spiroforme and Clostridium perfringens type E iota enterotoxaemia in rabbits. Eur. J. Chemother. Antibiot. 2:143-144. 71. Carman, R. J., and S. P. Borriello. 1984. Infectious nature of Clostridium spiroforme-mediated rabbit enterotoxaemia. Vet. Microbiol. 9:497-502. [PubMed]. 72. Carman, R. J., and R. H. Evans. 1984. Experimental and spontaneous clostridial enteropathies of laboratory and free living lagomorphs. Lab. Anim. Sci. 34:443-452. [PubMed]. 73. Carman, R. J., S. Perelle, and M. R. Popoff. 1997. Binary toxins from Clostridium spiroforme and Clostridium perfringens, p. 359-367. In J. Rood, B. A. McClane, G. Songer, and R. Titball (ed.), The clostridia: molecular biology and pathogenesis. Academic Press, Inc., New York, N.Y. 74. Carman, R. J., R. L. van Tassell, and T. D. Wilkins. 1987. Production of iota toxin by Clostridium spiroforme: a requirement for divalent cations. Vet. Microbiol. 15:115-120. [PubMed]. 75. Carman, R. J., and T. D. Wilkins. 1991. In vitro susceptibility of rabbit strains of Clostridium spiroforme to antimicrobial agents. Vet. Microbiol. 28:391-397. [PubMed]. 76. Carroll, S. F., and R. J. Collier. 1984. NAD binding site of diphtheria toxin: identification of a residue within the nicotinamide subsite by photochemical modification with NAD. Proc. Natl. Acad. Sci. USA 81:3307-3311. [PubMed]. 77. Cataldi, A., E. Labruyere, and M. Mock. 1990. Construction and characterization of a protective antigen deficient Bacillus anthracis strain. Mol. Microbiol. 4:1111-1117. [PubMed]. 78. Chardin, P., and F. McCormick. 1999. Brefeldin A: the advantage of being uncompetitive. Cell 97:153-155. [PubMed]. 79. Chaudry, G. J., M. Moayeri, S. Liu, and S. H. Leppla. 2002. Quickening the pace of anthrax research: three advances point towards possible therapies. Trends Microbiol. 10:58-62. [PubMed]. 80. Chauhan, V., and R. Bhatnagar. 2002. Identification of amino acid residues of anthrax protective antigen involved in binding with lethal factor. Infect. Immun. 70:4477-4484. [PubMed]. 81. Cheng, P. C., M. L. Dykstra, R. N. Mitchell, and S. K. Pierce. 1999. A role for lipid rafts in B cell antigen receptor signaling and antigen targeting. J. Exp. Med. 190:1549-1560. [PubMed]. 82. Choe, S., M. J. Bennett, G. Fujii, P. M. G. Curmi, K. A. Kantardjieff, R. J. Collier, and D. Eisenberg. 1992. The crystal structure of diphtheria toxin. Nature 357:216-222. [PubMed]. 83. Chopra, A. P., S. A. Boone, X. Liang, and N. S. Duesbery. 2003. Anthrax lethal factor proteolysis and inactivation of MAPK kinase. J. Biol. Chem. 278:9402-9406. [PubMed]. 84. Chowdhury, H. H., M. Kreft, and R. Zorec. 2002. Distinct effect of actin cytoskeleton disassembly on exo- and endo-cytic events in a membrane patch of rat melanotrophs. J. Physiol. 545:879-886. [PubMed]. 85. Chowdhury, H. H., M. R. Popoff, and R. Zorec. 1999. Actin cytoskeleton depolymerization with Clostridium spiroforme toxin enhances the secretory activity of rat melanotrophs. J. Physiol. 521:389-395. [PubMed]. 86. Cirino, N. M., D. Sblattero, D. Allen, S. R. Peterson, J. D. Marks, P. J. Jackson, A. Bradbury, and B. E. Lehnert. 1999. Disruption of anthrax toxin binding with the use of human antibodies and competitive inhibitors. Infect. Immun. 67:2957-2963. [PubMed]. 87. Confer, D. L., and J. W. Eaton. 1982. Phagocyte impotence caused by an invasive bacterial cyclase. Science 217:948-950. [PubMed]. 88. Considine, R. V., and L. L. Simpson. 1991. Cellular and molecular actions of binary toxins possessing ADP-ribosyltransferase activity. Toxicon 29:913-936. [PubMed]. 89. Considine, R. V., L. L. Simpson, and J. R. Sherwin. 1992. Botulinum C 2 toxin and steroid production in adrenal Y-1 cells: the role of microfilaments in the toxin-induced increase in steroid release. J. Pharmacol. Exp. Ther. 260:859-864. [PubMed]. 90. Coulson, N. M., M. Fulop, and R. W. Titball. 1994. Bacillus anthracis protective antigen, expressed in Salmonella typhimurium SL 3261, affords protection against anthrax spore challenge. Vaccine 12:1395-1401. [PubMed]. 91. Cummings, R. T., S. P. Salowe, B. R. Cunningham, J. Wiltsie, Y. W. Park, L. M. Sonatore, D. Wisniewski, C. M. Douglas, J. D. Hermes, and E. M. Scolnick. 2002. A peptide-based fluorescence resonance energy transfer assay for Bacillus anthracis lethal factor protease. Proc. Natl. Acad. Sci. USA 99:6603-6606. [PubMed]. 92. Cunningham, K., D. B. Lacy, J. Mogridge, and R. J. Collier. 2002. Mapping the lethal factor and edema factor binding sites on oligomeric anthrax protective antigen. Proc. Natl. Acad. Sci. USA 99:7049-7053. [PubMed]. 93. Czeczulin, J. R., P. C. Hanna, and B. A. McClane. 1993. Cloning, nucleotide sequencing, and expression of the Clostridium perfringens enterotoxin gene in Escherichia coli. Infect. Immun. 61:3429-3439. [PubMed]. 94. Dai, Z., J. C. Sirard, M. Mock, and T. M. Koehler. 1995. The atxA gene product activates transcription of the anthrax toxin genes and is essential for virulence. Mol. Microbiol. 16:1171-1181. [PubMed]. 95. Daube, G., B. China, P. Simon, K. Hvala, and J. Mainil. 1994. Typing of Clostridium perfringens by in vitro amplification of toxin genes. J. Appl. Bacteriol. 77:650-655. [PubMed]. 96. Daube, G., P. Simon, B. Limbourg, C. Manteca, J. Mainil, and A. Kaeckenbeeck. 1996. Hybridization of 2659 Clostridium perfringens isolates with gene probes for seven toxins (α, β, , ι, θ, μ, and enterotoxin) and for sialidase. Am. J. Vet. Res. 57:496-501. [PubMed]. 97. Devriese, P. P. 1999. On the discovery of Clostridium botulinum. J. Hist. Neurosci. 8:43-50. [PubMed]. 97a. Dixon, T. C., A. A. Fadl, T. M. Koehler, J. A. Swanson, and P. C. Hanna. 2000. Early Bacillus anthracis-macrophage interactions: intracellular survival and escape. Cell. Microbiol. 2:453-463. [PubMed]. 98. Dixon, T. C., M. Meselson, J. Guillemin, and P. C. Hanna. 1999. Anthrax. N. Engl. J. Med. 341:815-825. [PubMed]. 99. Djouder, N., U. Prepens, K. Aktories, and A. Cavalié. 2000. Inhibition of calcium release-activated calcium current by Rac/Cdc42-inactivating clostridial cytotoxins in RBL cells. J. Biol. Chem. 275:18732-18738. [PubMed]. 100. Dobbelstein, M. 2003. Viruses in therapy—royal road or dead end? Virus Res. 92:219-221. [PubMed]. 101. Doling, A. M., J. D. Ballard, H. Shen, K. M. Krishna, R. Ahmed, R. J. Collier, and M. N. Starnbach. 1999. Cytotoxic T-lymphocyte epitopes fused to anthrax toxin induce protective antiviral immunity. Infect. Immun. 67:3290-3296. [PubMed]. 102. Dreikhausen, U., G. Varga, F. Hofmann, H. Barth, K. Aktories, K. Resch, and M. Szamel. 2001. Regulation by rho family GTPases of IL-1 receptor induced signaling: C3-like chimeric toxin and Clostridium difficile toxin B inhibit signaling pathways involved in IL-2 gene expression. Eur. J. Immunol. 31:1610-1619. [PubMed]. 103. Drum, C. L., Y. Shen, P. A. Rice, A. Bohm, and W. J. Tang. 2001. Crystallization and preliminary X-ray study of the edema factor exotoxin adenylyl cyclase domain from Bacillus anthracis in the presence of its activator, calmodulin. Acta. Crystallogr. Ser. D. 57:1881-1884. [PubMed]. 104. Drum, C. L., S. Z. Yan, J. Bard, Y. Q. Shen, D. Lu, S. Soelaiman, Z. Grabarek, A. Bohm, and W. J. Tang. 2002. Structural basis for the activation of anthrax adenylyl cyclase exotoxin by calmodulin. Nature 415:396-402. [PubMed]. 105. Drum, C. L., S. Z. Yan, R. Sarac, Y. Mabuchi, K. Beckingham, A. Bohm, Z. Grabarek, and W. J. Tang. 2000. An extended conformation of calmodulin induces interactions between the structural domains of adenylyl cyclase from Bacillus anthracis to promote catalysis. J. Biol. Chem. 275:36334-36340. [PubMed]. 106. Duesbery, N. S., and G. F. Vande Woude. 1999. Anthrax lethal factor causes proteolytic inactivation of mitogen-activated protein kinase kinase. J. Appl. Microbiol. 87:289-293. [PubMed]. 107. Duesbery, N. S., C. P. Webb, S. H. Leppla, V. M. Gordon, K. R. Klimpel, T. D. Copeland, N. G. Ahn, M. K. Oskarsson, K. Fukasawa, K. D. Paull, and G. F. Vande Woude. 1998. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280:734-737. [PubMed]. 108. Eaton, P., and D. S. Fernie. 1980. Enterotoxaemia involving Clostridium perfringens iota toxin in a hysterectomy-derived rabbit colony. Lab. Anim. 14:347-351. [PubMed]. 109. Eckhardt, M., H. Barth, D. Blöcker, and K. Aktories. 2000. Binding of Clostridium botulinum C2 toxin to asparagine-linked complex and hybrid carbohydrates. J. Biol. Chem. 275:2328-2334. [PubMed]. 110. Egelman, E. H. 2001. Actin allostery again? Nat. Struct. Biol. 8:735-736. [PubMed]. 111. Ellis, T. M., A. R. Gregory, and G. D. Logue. 1991. Evaluation of a toxoid for protection of rabbits against enterotoxaemia experimentally induced by trypsin-activated supernatant of Clostridium spiroforme. Vet. Microbiol. 28:93-102. [PubMed]. 112. Enserink, M. 2002. Anthrax. “Borrowed immunity” may save future victims. Science 295:777. 113. Ermert, L., H. Brückner, D. Walmrath, F. Grimminger, K. Aktories, N. Suttorp, H.-R. Duncker, and W. Seeger. 1995. Role of endothelial cytoskeleton in high-permeability edema due to botulinum C 2 toxin in perfused rabbit lungs. Am. J. Physiol. 268:L753-L761. [PubMed]. 114. Ermert, L., H.-R. Duncker, H. Bruckner, F. Grimminger, T. Hansen, R. Rossig, K. Aktories, and W. Seeger. 1997. Ultrastructural changes of lung capillary endothelium in response to botulinum C2 toxin. J. Appl. Physiol. 82:382-388. [PubMed]. 115. Ermert, L., R. Rossig, T. Hansen, H. Schutte, K. Aktories, and W. Seeger. 1996. Differential role of actin in lung endothelial and epithelial barrier properties in perfused rabbit lungs. Eur. Respir. J. 9:93-99. [PubMed]. 116. Erwin, J. L., L. M. DaSilva, S. Bavari, S. F. Little, A. M. Friedlander, and T. C. Chanh. 2001. Macrophage-derived cell lines do not express proinflammatory cytokines after exposure to Bacillus anthracis lethal toxin. Infect. Immun. 69:1175-1177. [PubMed]. 117. Escuyer, V., and R. J. Collier. 1991. Anthrax protective antigen interacts with a specific receptor on the surface of CHO-K1 cells. Infect. Immun. 59:3381-3386. [PubMed]. 118. Ezzell, J. W., and T. G. Abshire. 1992. Serum protease cleavage of Bacillus anthracis protective antigen. J. Gen. Microbiol. 138:543-549. [PubMed]. 119. Fach, P., and M. R. Popoff. 1997. Detection of enterotoxigenic Clostridium perfringens in food and fecal samples with a duplex PCR and the slide agglutination test. Appl. Environ. Microbiol. 63:4232-4236. [PubMed]. 120. Falnes, P. O., S. Choe, I. H. Madshus, B. A. Wilson, and S. Olsnes. 1994. Inhibition of membrane translocation of diphtheria toxin A-fragment by internal disulfide bridges. J. Biol. Chem. 269:8402-8407. [PubMed]. 121. Fellows, P. F., M. K. Linscott, B. E. Ivins, M. L. Pitt, C. A. Rossi, P. H. Gibbs, and A. M. Friedlander. 2001. Efficacy of a human anthrax vaccine in guinea pigs, rabbits, and rhesus macaques against challenge by Bacillus anthracis isolates of diverse geographical origin. Vaccine 19:3241-3247. [PubMed]. 122. Fernie, D. S., J. M. Knights, R. O. Thomson, and R. J. Carman. 1984. Rabbit enterotoxaemia: purification and preliminary characterization of a toxin produced by Clostridium spiroforme. FEMS Microbiol. Lett. 21:207-211. 122a. Fine, A. M., J. B. Wong, H. S. Fraser, G. R. Fleisher, and K. D. Mandl. 2004. Is it influenza or anthrax? A decision analytic approach to the treatment of patients with influenza-like illnesses. Ann. Emerg. Med. 43:318-328. [PubMed]. 123. Finkelstein, A. 1994. The channel formed in planar lipid bilayers by the protective antigen component of anthrax toxin. Toxicology 87:29-41. [PubMed]. 124. Fivaz, M., L. Abrami, Y. Tsitrin, and F. G. van der Goot. 2001. Not as simple as just punching a hole. Toxicon 39:1637-1645. [PubMed]. 125. Flick-Smith, H. C., J. E. Eyles, R. Hebdon, E. L. Waters, R. J. Beedham, T. J. Stagg, J. Miller, H. O. Alpar, L. W. Baillie, and E. D. Williamson. 2002. Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice. Infect. Immun. 70:2022-2028. [PubMed]. 126. Flick-Smith, H. C., N. J. Walker, P. Gibson, H. Bullifent, S. Hayward, J. Miller, R. W. Titball, and E. D. Williamson. 2002. A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection. Infect. Immun. 70:1653-1656. [PubMed]. 127. Fox, G. E., E. Stackabrandt, R. B. Hespell, J. Gibson, J. Mariloff, T. A. Dyer, R. S. Wolfe, W. E. Balch, R. S. Tanner, L. J. Magrum, et al. 1980. The phylogeny of prokaryotes. Science 209:457-463. [PubMed]. 128. Francis, J. W., R. H. Brown Jr., D. Figueiredo, M. P. Remington, O. Castillo, M. A. Schwarzschild, P. S. Fishman, J. R. Murphy, and J. C. vanderSpek. 2000. Enhancement of diphtheria toxin potency by replacement of the receptor binding domain with tetanus toxin C-fragment: a potential vector for delivering heterologous proteins to neurons. J. Neurochem. 74:2528-2536. [PubMed]. 129. Frankel, A. E., B. L. Powell, N. S. Duesbery, G. F. Vande Woude, and S. H. Leppla. 2002. Anthrax fusion protein therapy of cancer. Curr. Protein Pept. Sci. 3:399-407. [PubMed]. 130. Frieben, W. R., and C. L. Duncan. 1973. Homology between enterotoxin protein and spore structural protein in Clostridium perfringens type A. Eur. J. Biochem. 39:393-401. [PubMed]. 131. Friedlander, A. M. 1986. Macrophages are sensitive to anthrax lethal toxin through an acid-dependent process. J. Biol. Chem. 261:7123-7126. [PubMed]. 132. Friedlander, A. M. 2000. Anthrax: clinical features, pathogenesis, and potential biological warfare threat. Curr. Clin. Top. Infect. Dis. 20:335-349. [PubMed]. 133. Friedlander, A. M., P. R. Pittman, and G. W. Parker. 1999. Anthrax vaccine. Evidence for safety and efficacy against inhalational anthrax. JAMA 282:2104-2106. [PubMed]. 134. Friedlander, A. M., S. L. Welkos, and B. E. Ivins. 2002. Anthrax vaccines. Curr. Top. Microbiol. Immunol. 271:33-60. [PubMed]. 135. Fritz, G., P. Schroeder, and K. Aktories. 1995. Isolation and characterization of a Clostridium botulinum C2 toxin-resistant cell line: evidence for possible involvement of the cellular C2II receptor in growth regulation. Infect. Immun. 63:2334-2340. [PubMed]. 136. Fry, D. C., S. A. Kuby, and A. S. Mildvan. 1986. ATP-binding site of adenylate kinase: mechanistic implications of its homology with ras-encoded p21, F 1-ATPase, and other nucleotide-binding proteins. Proc. Natl. Acad. Sci. USA 83:907-911. [PubMed]. 137. Fujii, N., T. Kubota, S. Shirakawa, K. Kimura, I. Ohishi, K. Moriishi, E. Isogai, and H. Isogai. 1996. Characterization of component-I gene of botulinum C2 toxin and PCR detection of its gene in clostridial species. Biochem. Biophys. Res. Commun. 220:353-359. [PubMed]. 137a. Fukao, T. 2004. Immune system paralysis by anthrax lethal toxin: the roles of innate and adaptive immunity. Lancet Infect. Dis. 4:166-170. [PubMed]. 138. Gao-Sheridan, S., S. Zhang, and R. J. Collier. 2003. Exchange characteristics of calcium ions bound to anthrax protective antigen. Biochem. Biophys. Res. Commun. 300:61-64. [PubMed]. 139. Garmory, H. S., R. W. Titball, K. F. Griffin, U. Hahn, R. Bohm, and W. Beyer. 2003. Salmonella enterica serovar typhimurium expressing a chromosomally integrated copy of the Bacillus anthracis protective antigen gene protects mice against an anthrax spore challenge. Infect. Immun. 71:3831-3836. [PubMed]. 140. Garred, O., E. Dubinina, A. Polessakaya, S. Olsnes, J. Kozlov, and K. Sandvig. 1997. Role of the disulfide bond in Shiga toxin A-chain for toxin entry into cells. J. Biol. Chem. 272:11414-11419. [PubMed]. 141. Garred, O., B. van Deurs, and K. Sandvig. 1995. Furin-induced cleavage and activation of Shiga toxin. J. Biol. Chem. 270:10817-10821. [PubMed]. 142. Gasman, S., S. Chasserot-Golaz, M. Popoff, D. Aunis, and M.-F. Bader. 1999. Involvement of Rho GTPases in calcium-regulated exocytosis from adrenal chromaffin cells. J. Cell Sci. 112:4763-4771. [PubMed]. 143. Gaur, R., P. K. Gupta, A. C. Banerjea, and Y. Singh. 2002. Effect of nasal immunization with protective antigen of Bacillus anthracis on protective immune response against anthrax toxin. Vaccine 20:2836-2839. [PubMed]. 144. Gaur, R., P. K. Gupta, A. Goyal, W. Wels, and Y. Singh. 2002. Delivery of nucleic acid into mammalian cells by anthrax toxin. Biochem. Biophys. Res. Commun. 297:1121-1127. [PubMed]. 145. Geipel, U., I. Just, and K. Aktories. 1990. Inhibition of cytochalasin D-stimulated G-actin ATPase by ADP-ribosylation with Clostridium perfringens iota toxin. Biochem. J. 266:335-339. [PubMed]. 146. Geipel, U., I. Just, B. Schering, D. Haas, and K. Aktories. 1989. ADP-ribosylation of actin causes increase in the rate of ATP exchange and inhibition of ATP hydrolysis. Eur. J. Biochem. 179:229-232. [PubMed]. 146a. Geric, B., S. Johnson, D. D. Gerding, M. Grabnar, and M. Rupnik. 2003. Frequency of binary toxin genes among Clostridium difficile strains that do not produce large clostridial toxins. J. Clin. Microbiol. 41:5227-5232. [PubMed]. 147. Gibert, M., S. Perelle, G. Daube, and M. R. Popoff. 1997. Clostridium spiroforme toxin genes are related to C. perfringens iota toxin genes but have a different genomic localization. Syst. Appl. Microbiol. 20:337-347. 148. Gibert, M., L. Petit, S. Raffestin, A. Okabe, and M. R. Popoff. 2000. Clostridium perfringens iota-toxin requires activation of both binding and enzymatic components for cytopathic activity. Infect. Immun. 68:3848-3853. [PubMed]. 149. Gilligan, P. H. 2002. Therapeutic challenges posed by bacterial bioterrorism threats. Curr. Opin. Microbiol. 5:489-495. [PubMed]. 149a. Gilmore, M. S., M. C. Callegan, and B. D. Jett. 1999. Enterococcus faecalis cytolysin and Bacillus cereus bi- and tri-component haemolysins, p. 419-434. In J. E. Alouf and J. H. Freer (ed.), The comprehensive sourcebook of bacterial protein toxins. Academic Press, Inc., New York, N.Y. 150. Gkiourtzidis, K., J. Frey, E. Bourtzi-Hatzopoulou, N. Iliadis, and K. Sarris. 2001. PCR detection and prevalence of alpha-, beta-, beta 2-, epsilon-, iota- and enterotoxin genes in Clostridium perfringens isolated from lambs with clostridial dysentery. Vet. Microbiol. 82:39-43. [PubMed]. 151. Gladstone, G. P. 1946. Immunity to anthrax. Protective antigen present in cell-free culture filtrates. Br. J. Exp. Pathol. 27:349-418. 152. Glick, M., D. D. Robinson, G. H. Grant, and W. G. Richards. 2002. Identification of ligand binding sites on proteins using a multi-scale approach. J. Am. Chem. Soc. 124:2337-2344. [PubMed]. 152a. Gold, J. A., Y. Hoshino, S. Hoshino, M. B. Jones, A. Nolan, and M. D. Weiden. 2004. Exogenous gamma and alpha/beta interferon rescues human macrophages from cell death induced by Bacillus anthracis. Infect. Immun. 72:1291-1297. [PubMed]. 153. Goletz, T. J., K. R. Klimpel, N. Arora, S. H. Leppla, J. M. Keith, and J. A. Berzofsky. 1997. Targeting HIV proteins to the major histocompatibility complex class I processing pathway with a novel gp120-anthrax toxin fusion protein. Proc. Natl. Acad. Sci. USA 94:12059-12064. [PubMed]. 154. Goletz, T. J., K. R. Klimpel, S. H. Leppla, J. M. Keith, and J. A. Berzofsky. 1997. Delivery of antigens to the MHC class I pathway using bacterial toxins. Hum. Immunol. 54:129-136. [PubMed]. 155. Gordon, V. M., K. R. Klimpel, N. Arora, M. A. Henderson, and S. H. Leppla. 1995. Proteolytic activation of bacterial toxins by eukaryotic cells is performed by furin and by additional cellular proteases. Infect. Immun. 63:82-87. [PubMed]. 156. Gordon, V. M., and S. H. Leppla. 1994. Proteolytic activation of bacterial toxins: role of bacterial and host cell proteases. Infect. Immun. 62:333-340. [PubMed]. 157. Gordon, V. M., S. H. Leppla, and E. L. Hewlett. 1988. Inhibitors of receptor-mediated endocytosis block the entry of Bacillus anthracis adenylate cyclase toxin but not that of Bordetella pertussis adenylate cyclase toxin. Infect. Immun. 56:1066-1069. [PubMed]. 158. Goyard, S., C. Orlando, J. M. Sabatier, E. Labruyere, J. d'Alayer, G. Fontan, J. van Rietschoten, M. Mock, A. Danchin, A. Ullmann, and A. Monneron. 1989. Identification of a common domain in calmodulin-activated eukaryotic and bacterial adenylate cyclases. Biochemistry 28:1964-1967. [PubMed]. 158a. Granum, P. E., and S. Brynestad. 1999. Bacterial toxin as food poisons, p. 669-681. In J. E. Alouf and J. H. Freer (ed.), The comprehensive sourcebook of bacterial protein toxins. Academic Press, Inc., New York, N.Y. 159. Grimminger, F., U. Sibelius, K. Aktories, I. Just, and W. Seeger. 1991. Suppression of cytoskeletal rearrangement in activated human neutrophils by botulinum C 2 toxin. Impact on cellular signal transduction. J. Biol. Chem. 266:19276-19282. [PubMed]. 160. Gruenberg, J., and K. E. Howell. 1989. Membrane traffic in endocytosis: insights from cell-free assays. Annu. Rev. Cell Biol. 5:453-481. [PubMed]. 161. Gu, M. L., S. H. Leppla, and D. M. Klinman. 1999. Protection against anthrax toxin by vaccination with a DNA plasmid encoding anthrax protective antigen. Vaccine 17:340-344. [PubMed]. 162. Guidi-Rontani, C. 2002. The alveolar macrophage: the Trojan horse of Bacillus anthracis. Trends. Microbiol. 10:405-409. [PubMed]. 162a. Guidi-Rontani, C., M. Levy, H. Ohayon, and M. Mock. 2001. Fate of germinated Bacillus anthracis spores in primary murine macrophages. Mol. Microbiol. 42:931-938. [PubMed]. 163. Guidi-Rontani, C., M. Weber-Levy, E. Labruyere, and M. Mock. 1999. Germination of Bacillus anthracis spores within alveolar macrophages. Mol. Microbiol. 31:9-17. [PubMed]. 164. Guidi-Rontani, C., M. Weber-Levy, M. Mock, and V. Cabiaux. 2000. Translocation of Bacillus anthracis lethal and oedema factors across endosome membranes. Cell Microbiol. 2:259-264. [PubMed]. 165. Guignot, J., M. Mock, and A. Fouet. 1997. AtxA activates the transcription of genes harbored by both Bacillus anthracis virulence plasmids. FEMS Microbiol. Lett. 147:203-207. [PubMed]. 166. Gülke, I., G. Pfeifer, J. Liese, M. Fritz, F. Hofmann, K. Aktories, and H. Barth. 2001. Characterization of the enzymatic component of the ADP-ribosyltransferase toxin CDTa from Clostridium difficile. Infect. Immun. 69:6004-6011. [PubMed]. 166a. Gupta, P. K., H. Chandra, R. Gaur, R. K. Kurupati, S. Chowdhury, V. Tandon, Y. Singh, and K. Maithal. 2003. Conformational fluctuations in anthrax protective antigen: a possible role of calcium in the folding pathway of the protein. FEBS Lett. 554:505-510. [PubMed]. 167. Gupta, P. K., R. K. Kurupati, H. Chandra, R. Gaur, V. Tandon, Y. Singh, and K. Maithal. 2003. Acid induced unfolding of anthrax protective antigen. Biochem. Biophys. Res. Commun. 311:229-232. [PubMed]. 168. Gupta, P., A. Singh, V. Chauhan, and R. Bhatnagar. 2001. Involvement of residues 147VYYEIGK153 in binding of lethal factor to protective antigen of Bacillus anthracis. Biochem. Biophys. Res. Commun. 280:158-163. [PubMed]. 169. Hahn, A., H. Barth, M. Kress, P. R. Mertens, and M. Goppelt-Strübe. 2002. Role of Rac and Cdc42 in lysophosphatidic acid-mediated cyclooxygenase-2 gene expression. Biochem. J. 362:33-40. [PubMed]. 169a. Hale, M. L., J. C. Marvaud, M. R. Popoff, and B. G. Stiles. 2004. Detergent-resistant membrane microdomains facilitate Ib oligomer formation and biological activity of Clostridium perfringens iota-toxin. Infect. Immun. 72:2186-2193. [PubMed]. 170. Han, S., A. S. Arvai, S. B. Clancy, and J. A. Tainer. 2001. Crystal structure and novel recognition motif of Rho ADP-ribosylating C3 exoenzyme from Clostridium botulinum: structural insights for recognition specificity and catalysis. J. Mol. Biol. 305:95-107. [PubMed]. 171. Han, S., J. A. Craig, C. D. Putnam, N. B. Carozzi, and J. A. Tainer. 1999. Evolution and mechanism from structures of an ADP-ribosylating toxin and NAD complex. Nat. Struct. Biol. 6:932-936. [PubMed]. 172. Hanna, P. 1998. Anthrax pathogenesis and host response. Curr. Top. Microbiol. Immunol. 225:13-35. [PubMed]. 173. Hanna, P. 1999. Lethal toxin actions and their consequences. J. Appl. Microbiol. 87:285-287. [PubMed]. 174. Hanna, P. C., D. Acosta, and R. J. Collier. 1993. On the role of macrophages in anthrax. Proc. Natl. Acad. Sci. USA 90:10198-10201. [PubMed]. 175. Hanna, P. C., S. Kochi, and R. J. Collier. 1992. Biochemical and physiological changes induced by anthrax lethal toxin in J774 macrophage-like cells. Mol. Biol. Cell 3:1269-1277. [PubMed]. 176. Hanna, P. C., B. A. Kruskal, R. A. Ezekowitz, B. R. Bloom, and R. J. Collier. 1994. Role of macrophage oxidative burst in the action of anthrax lethal toxin. Mol. Med. 1:7-18. [PubMed]. 177. Harder, T., P. Scheiffele, P. Verkade, and K. Simons. 1998. Lipid domain structure of the plasma membrane revealed by patching of membrane components. J. Cell Biol. 141:929-942. [PubMed]. 178. Hart, B., and P. Hooper. 1967. Enterotoxaemia of calves due to Clostridium welchii type E. Aust. Vet. J. 43:360-363. [PubMed]. 178a. Haug, G., K. Aktories, and H. Barth. 2003. The host cell chaperone Hsp90 is necessary for cytotoxic action of the binary iota-like toxins. Infect. Immun. 72:3066-3068. 179. Haug, G., J. Leemhuis, D. Tiemann, D. K. Meyer, K. Aktories, and H. Barth. 2003. The host cell chaperone Hsp90 is essential for translocation of the binary Clostridium botulinum C2 toxin into the cytosol. J. Biol. Chem. 278:32266-32274. [PubMed]. 180. Helgason, E., O. A. Okstad, D. A. Caugant, H. A. Johansen, A. Fouet, M. Mock, I. Hegna, and A.-B. Kolsto. 2000. Bacillus anthracis, Bacillus cereus, and Bacillus thuringiensis—one species on the basis of genetic evidence. Appl. Environ. Microbiol. 66:2627-2630. [PubMed]. 181. Hirst, T. R. 1999. Cholera toxin and Escherichia coli heat-labile enterotoxin, p. 104-129. In J. E. Alouf and J. H. Freer (ed.), The comprehensive sourcebook of bacterial protein Toxins. Academic Press, Inc., New York, N.Y. 182. Hoffmaster, A. R., and T. M. Koehler. 1997. The anthrax toxin activator gene atxA is associated with CO 2-enhanced non-toxin gene expression in Bacillus anthracis. Infect. Immun. 65:3091-3099. [PubMed]. 182a. Hofmann, F., A. Herrmann, E. Habermann, and C. von Eichel-Streiber. 1995. Sequencing and analysis of the gene encoding the α-toxin of Clostridium novyi proves its homology to toxins A and B of Clostridium difficile. Mol. Gen. Gene. 247:670-679. 182b. L. V. Holdeman, E. P. Cato, and W. E. C. Moore (ed.) 1977. VPI anaerobe laboratory manual, p. 131-133. Southern Printing Co., Blacksburg, Va. 183. Holmes, H. T., R. J. Sonn, and N. M. Patton. 1988. Isolation of Clostridium spiroforme from rabbits. Lab. Anim. Sci. 38:167-168. [PubMed]. 184. Hoover, D. L., A. M. Friedlander, L. C. Rogers, I. K. Yoon, R. L. Warren, and A. S. Cross. 1994. Anthrax edema toxin differentially regulates lipopolysaccharide induced monocyte production of tumor necrosis factor alpha and interleukin-6 by increasing intracellular cyclic AMP. Infect. Immun. 62:4432-4439. [PubMed]. 185. Iacono-Connors, L. C., S. L. Welkos, B. E. Ivins, and J. M. Dalrymple. 1991. Protection against anthrax with recombinant virus-expressed protective antigen in experimental animals. Infect. Immun. 59:1961-1965. [PubMed]. 186. Ivanova, N., A. Sorokin, I. Anderson, N. Galleron, B. Candelon, V. Kapatral, A. Bhattacharyya, G. Reznik, N. Mikhailova, A. Lapidus, L. Chu, M. Mazur, E. Goltsman, N. Larsen, M. D'Souza, T. Walunas, Y. Grechkin, G. Pusch, R. Haselkorn, M. Fonstein, S. D. Ehrlich, R. Overbeek, and N. Kyrpides. 2003. Genome sequence of Bacillus cereus and comparative analysis with Bacillus anthracis. Nature 423:87-91. [PubMed]. 187. Ivins, B. E., M. L. Pitt, P. F. Fellows, J. W. Farchaus, G. E. Benner, D. M. Waag, S. F. Little, G. W. Anderson, P. H. Gibbs, and A. M. Friedlander. 1998. Comparative efficacy of experimental anthrax vaccine candidates against inhalation anthrax in rhesus macaques. Vaccine 16:1141-1148. [PubMed]. 188. Ivins, B. E., S. L. Welkos, G. B. Knudson, and S. F. Little. 1990. Immunization against anthrax with aromatic compound-dependent (Aro −) mutants of Bacillus anthracis and with recombinant strains of Bacillus subtilis that produce anthrax protective antigen. Infect. Immun. 58:303-308. [PubMed]. 189. Iwasaki, M., I. Ohishi, and G. Sakaguchi. 1980. Evidence that botulinum C2 toxin has two dissimilar components. Infect. Immun. 29:390-394. [PubMed]. 190. Jendrek, S., S. F. Little, S. Hem, G. Mitra, and S. Giardina. 2003. Evaluation of the compatibility of a second generation recombinant anthrax vaccine with aluminum- containing adjuvants. Vaccine 21:3011-3018. [PubMed]. 191. Jensen, W. I., and R. M. Duncan. 1980. The susceptibility of the mallard duck ( Anas platyrhynchos) to Clostridium botulinum C2 toxin. Jpn. J. Med. Sci. Biol. 33:81-86. [PubMed]. 192. Jernigan, J. A., D. S. Stephens, D. A. Ashford, C. Omenaca, M. S. Topiel, M. Galbraith, M. Tapper, T. L. Fisk, S. Zaki, T. Popovic, R. F. Meyer, C. P. Quinn, S. A. Harper, S. K. Fridkin, J. J. Sejvar, C. W. Shepard, M. McConnell, J. Guarner, W. J. Shieh, J. M. Malecki, J. L. Gerberding, J. M. Hughes, and B. A. Perkins. 2001. Bioterrorism-related inhalational anthrax: the first 10 cases reported in the United States. Emerg. Infect. Dis. 7:933-944. [PubMed]. 193. Jin, F., O. Matsushita, S. Katayama, S. Jin, C. Matsushita, J. Minami, and A. Okabe. 1996. Purification, characterization, and primary structure of Clostridium perfringens lambda-toxin, a thermolysin-like metalloprotease. Infect. Immun. 64:230-237. [PubMed]. 194. Jooss, K., and N. Chirmule. 2003. Immunity to adenovirus and adeno-associated viral vectors: implications for gene therapy. Gene Ther. 10:955-963. [PubMed]. 195. Jun, C. D., M. K. Han, U. H. Kim, and H. T. Chung. 1996. Nitric oxide induces ADP-ribosylation of actin in murine macrophages: association with the inhibition of pseudopodia formation, phagocytic activity, and adherence on a laminin substratum. Cell Immunol. 174:25-34. [PubMed]. 196. Jung, M., I. Just, J. van Damme, J. Vandekerckhove, and K. Aktories. 1993. NAD- binding site of the C3-like ADP-ribosyltransferase from Clostridium limosum. J. Biol. Chem. 268:23215-23218. [PubMed]. 197. Jupin, C., S. Anderson, C. Damais, J. E. Alouf, and M. Parant. 1988. Toxic shock syndrome toxin 1 as an inducer of human tumor necrosis factors and gamma interferon. J. Exp. Med. 167:752-761. [PubMed]. 198. Just, I., U. Geipel, A. Wegner, and K. Aktories. 1990. De-ADP-ribosylation actin by Clostridium perfringens iota-toxin and Clostridium botulinum C2 toxin. Eur. J. Biochem. 192:723-727. [PubMed]. 199. Just, I., E. S. Hennessey, D. R. Drummond, K. Aktories, and J. C. Sparrow. 1993. ADP-ribosylation of Drosophila indirect-flight-muscle actin and arthrin by Clostridium botulinum C2 toxin and Clostridium perfringens iota toxin. Biochem. J. 291:409-412. [PubMed]. 200. Just, I., C. Mohr, G. Schallehn, L. Menard, J. R. Didsbury, J. Vandekerckhove, J. van Damme, and K. Aktories. 1992. Purification and characterization of an ADP-ribosyltransferase produced by Clostridium limosum. J. Biol. Chem. 267:10274-10280. [PubMed]. 201. Just, I., M. Wille, C. Chaponnier, and K. Aktories. 1993. Gelsolin-actin complex is target for ADP-ribosylation by Clostridium botulinum C2 toxin in intact human neutrophils. Eur. J. Pharmacol. Mol. Pharmacol. 246:293-297. 201a. Karginov, V. A., T. M. Robinson, J. Riemenschneider, B. Golding, M. Kennedy, J. Shiloach, and K. Alibek. 2004. Treatment of anthrax infection with combination of ciprofloxacin and antibodies to protective antigen of Bacillus anthracis. FEMS Immunol. Med. Microbiol. 40:71-74. [PubMed]. 202. Katz, L., J. T. Lamont, J. S. Trier, E. B. Sonnenblick, S. W. Rothman, S. A. Broitman, and S. Rieth. 1978. Experimental clindamycin associated colitis in rabbits. Evidence for toxin-mediated mucosal damage. Gastroenterology 74:246-252. [PubMed]. 203. Keim, P., and K. L. Smith. 2002. Bacillus anthracis evolution and epidemiology. Curr. Top. Microbiol. Immunol. 271:21-32. [PubMed]. 204. Keppie, J., P. W. Harris-Smith, and H. Smith. 1963. The chemical basis of the virulence of Bacillus anthracis. IX. Its aggressins and their mode of action. Br. J. Exp. Pathol. 44:446-453. [PubMed]. 205. Khanna, H., A. P. Chopra, N. Arora, A. Chaudhry, and Y. Singh. 2001. Role of residues constituting the 2β1 strand of domain II in the biological activity of anthrax protective antigen. FEMS Microbiol. Lett. 199:27-31. [PubMed]. 206. Khanna, H., P. K. Gupta, A. Singh, R. Chandra, and Y. Singh. 2001. Participation of residue F552 in domain III of the protective antigen in the biological activity of anthrax lethal toxin. Biol. Chem. 382:941-946. [PubMed]. 207. Kim, S. O., Q. Jing, K. Hoebe, B. Beutler, N. S. Duesbery, and J. Han. 2003. Sensitizing anthrax lethal toxin-resistant macrophages to lethal toxin-induced killing by tumor necrosis factor-alpha. J. Biol. Chem. 278:7413-7421. [PubMed]. 208. Kimura, K., T. Kubota, I. Ohishi, E. Isogai, H. Isogai, and N. Fujii. 1998. The gene for component-II of botulinum C2 toxin. Vet. Microbiol. 62:27-34. [PubMed]. 208a. Kirby, J. E. 2004. Anthrax lethal toxin induces human endothelial cell apoptosis. Infect. Immun. 72:430-439. [PubMed]. 209. Kistner, A., and E. Habermann. 1992. Reductive cleavage of tetanus toxin and botulinum neurotoxin A by the thioredoxin system from brain. Evidence for two redox isomers of tetanus toxin. Naunyn Schmiedebergs Arch. Pharmacol. 345:227-234. 210. Klimpel, K. R., N. Arora, and S. H. Leppla. 1994. Anthrax toxin lethal factor contains a zinc metalloprotease consensus sequence which is required for lethal toxin activity. Mol. Microbiol. 13:1093-1100. [PubMed]. 211. Klimpel, K. R., S. S. Molloy, G. Thomas, and S. H. Leppla. 1992. Anthrax toxin protective antigen is activated by a cell surface protease with the sequence specificity and catalytic properties of furin. Proc. Natl. Acad. Sci. USA 89:10277-10281. [PubMed]. 212. Klussmann, E., G. Tamma, D. Lorenz, B. Wiesner, K. Maric, F. Hofmann, K. Aktories, G. Valenti, and W. Rosenthal. 2001. An inhibitory role of Rho in the vasopressin-mediated translocation of aquaporin-2 into cell membranes of renal principal cells. J. Biol. Chem. 276:20451-20457. [PubMed]. 213. Knapp, O., R. Benz, M. Gibert, J. C. Marvaud, and M. R. Popoff. 2002. Interaction of Clostridium perfringens iota-toxin with lipid bilayer membranes. J. Biol. Chem. 277:6143-6152. [PubMed]. 213a. Kobiler, D., Y. Gozes, H. Rosenberg, D. Marcus, S. Reuveny, and Z. Altboum. 2002. Efficiency of protection of guinea pigs against infection with Bacillus anthracis spores by passive immunization. Infect. Immun. 70:544-550. [PubMed]. 214. Koehler T. M. 2002. Bacillus anthracis genetics and virulence gene regulation. Curr. Top. Microbiol. Immunol. 271:143-164. [PubMed]. 215. Koehler, T. M., and R. J. Collier. 1991. Anthrax toxin protective antigen: low-pH- induced hydrophobicity and channel formation in liposomes. Mol. Microbiol. 5:1501-1506. [PubMed]. 216. Koo, H.-M., M. VanBrocklin, M. J. McWilliams, S. H. Leppla, N. S. Duesbery, and G. F. Vande Woude. 2002. Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase. Proc. Natl. Acad. Sci. USA 99:3052-3057. [PubMed]. 217. Krakauer, T. 1995. Inhibition of toxic shock syndrome toxin-1-induced cytokine production and T cell activation by interleukin-10, interleukin-4, and dexamethasone. J. Infect. Dis. 172:988-992. [PubMed]. 218. Krakauer, T., and B. G. Stiles. 2003. Staphylococcal enterotoxins, toxic shock syndrome toxin-1, and streptococcal pyrogenic exotoxins: some basic biology of bacterial superantigens. Recent Res. Dev. Infect. Immun. 1:1-27. 219. Kumar, P., N. Ahuja, and R. Bhatnagar. 2001. Purification of anthrax edema factor from Escherichia coli and identification of residues required for binding to anthrax protective antigen. Infect. Immun. 69:6532-6536. [PubMed]. 220. Kumar, P., N. Ahuja, and R. Bhatnagar. 2002. Anthrax edema toxin requires influx of calcium for inducing cyclic AMP toxicity in target cells. Infect. Immun. 70:4997-5007. [PubMed]. 221. Kurazono, H., M. Hosokawa, H. Matsuda, and G. Sakaguchi. 1987. Fluid accumulation in the ligated intestinal loop and histopathological changes of the intestinal mucosa caused by Clostridium botulinum C2 toxin in the pheasant and chicken. Res. Vet. Sci. 42:349-353. [PubMed]. 222. Kushner, N., D. Zhang, N. Touzjian, M. Essex, J. Lieberman, and Y. Lu. 2003. A fragment of anthrax lethal factor delivers proteins to the cytosol without requiring protective antigen. Proc. Natl. Acad. Sci. USA 100:6652-6657. [PubMed]. 223. Labruyere E., M. Mock, D. Ladant, S. Michelson, A. M. Gilles, B. Laoide, and O. Barzu. 1990. Characterization of ATP and calmodulin-binding properties of a truncated form of Bacillus anthracis adenylate cyclase. Biochemistry 29:4922-4928. [PubMed]. 224. Lacy, D. B., M. Mourez, A. Fouassier, and R. J. Collier. 2002. Mapping the anthrax protective antigen binding site on the lethal and edema factors. J. Biol. Chem. 277:3006-3010. [PubMed]. 225. Lafont, F., G. Tran Van Nhieu, K. Hanada, P. Sansonetti, and F. G. van der Goot. 2002. Initial steps of Shigella infection depend on the cholesterol/sphingolipid raft-mediated CD44-IpaB interaction. EMBO J. 21:4449-4457. [PubMed]. 226. Lamont, J. T., E. B. Sonnenblick, and S. Rothman. 1979. Role of clostridial toxin in the pathogenesis of clindamycin colitis in rabbits. Gastroenterology 76:356-361. [PubMed]. 227. Lee, J. S., A. G. Hadjipanayis, and S. L. Welkos. 2003. Venezuelan equine encephalitis virus-vectored vaccines protect mice against anthrax spore challenge. Infect. Immun. 71:1491-1496. [PubMed]. 228. Lencer, W. I., C. Constable, S. Moe, P. A. Rufo, A. Wolf, M. G. Jobling, S. P. Ruston, J. L. Madara, R. K. Holmes, and T. R. Hirst. 1997. Proteolytic activation of cholera toxin and Escherichia coli labile toxin by entry into host epithelial cells: signal transduction by a protease-resistant toxin variant. J. Biol. Chem. 272:15562-15568. [PubMed]. 229. Leppla, S. H. 1982. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations in eukaryotic cells. Proc. Natl. Acad. Sci. USA 79:3162-3166. [PubMed]. 230. Leppla, S. H. 1999. The bifactorial Bacillus anthracis lethal and oedema toxins, p. 243-263. In J. E. Alouf and J. H. Freer (ed.), The comprehensive sourcebook of bacterial protein toxins. Academic Press, Inc., New York, N.Y. 231. Leppla, S. H., N. Arora, and M. Varughese. 1999. Anthrax toxin fusion proteins for intracellular delivery of macromolecules. J. Appl. Microbiol. 87:284. [PubMed]. 232. Leppla, S. H., J. B. Robbins, R. Schneerson, and J. Shiloach. 2002. Development of an improved vaccine for anthrax. J. Clin. Investig. 110:141-144. [PubMed]. 233. Levens, D. L. 2003. Reconstructing MYC. Genes Dev. 17:1071-1077. [PubMed]. 234. Li, G., E. Rungger-Brändle, I. Just, J.-C. Jonas, K. Aktories, and C. B. Wollheim. 1994. Effect of disruption of actin filaments by Clostridium botulinum C2 toxin on insulin secretion in HIT-T15 cells and pancreatic islets. Mol. Biol. Cell 5:1199-1213. [PubMed]. 235. Li, M., F. Dyda, I. Benhar, I. Pastan, and D. R. Davies. 1996. Crystal structure of the catalytic domain of Pseudomonas exotoxin A complexed with a nicotinamide adenine dinucleotide analog: implications for the activation process and for ADP ribosylation. Proc. Natl. Acad. Sci. USA 93:6902-6906. [PubMed]. 236. Linseman, D. A., T. Laessig, M. K. Meintzer, M. McClure, H. Barth, K. Aktories, and K. A. Heidenreich. 2001. An essential role for Rac/Cdc42 GTPases in cerebellar granule neuron survival. J. Biol. Chem. 276:39123-39131. [PubMed]. 237. Little, S. F., and B. E. Ivins. 1999. Molecular pathogenesis of Bacillus anthracis infection. Microbes Infect. 1:131-139. [PubMed]. 238. Little, S. F., B. E. Ivins, P. F. Fellows, and A. M. Friedlander. 1997. Passive protection by polyclonal antibodies against Bacillus anthracis infection in guinea pigs. Infect. Immun. 65:5171-5175. [PubMed]. 239. Little, S. F., S. H. Leppla, J. W. Burnett, and A. M. Friedlander. 1994. Structure-function analysis of Bacillus anthracis edema factor by using monoclonal antibodies. Biochem. Biophys. Res. Commun. 199:676-682. [PubMed]. 240. Little, S. F., S. H. Leppla, and E. Cora. 1988. Production and characterization of monoclonal antibodies to the protective antigen component of Bacillus anthracis toxin. Infect. Immun. 56:1807-1813. [PubMed]. 241. Little, S. F., S. H. Leppla, and A. M. Friedlander. 1990. Production and characterization of monoclonal antibodies against the lethal factor component of Bacillus anthracis lethal toxin. Infect. Immun. 58:1606-1613. [PubMed]. 242. Little, S. F, and J. R. Lowe. 1991. Location of receptor-binding region of protective antigen from Bacillus anthracis. Biochem. Biophys. Res. Commun. 180:531-537. [PubMed]. 243. Little, S. F., J. M. Novak, J. R. Lowe, S. H. Leppla, Y. Singh, K. R. Klimpel, B. C. Lidgerding, and A. M. Friedlander. 1996. Characterization of lethal factor binding and cell receptor binding domains of protective antigen of Bacillus anthracis using monoclonal antibodies. Microbiology 142:707-715. [PubMed]. 244. Liu, S., H. Aaronson, D. J. Mitola, S. H. Leppla, and T. H. Bugge. 2003. Potent antitumor activity of a urokinase-activated engineered anthrax toxin. Proc. Natl. Acad. Sci. USA 100:657-662. [PubMed]. 245. Liu, S., and S. H. Leppla. 2003. Cell surface tumor endothelium marker 8 cytoplasmic tail-independent anthrax toxin binding, proteolytic processing, oligomer formation, and internalization. J. Biol. Chem. 278:5227-5234. [PubMed]. 246. Liu, S., R. L. Schubert, T. H. Bugge, and S. H. Leppla. 2003. Anthrax toxin: structures, functions and tumour targeting. Exp. Opin. Biol. Ther. 3:843-853. 246a. Locht, C., and R. Antoine. 1999. Bordetella pertussis protein toxins, p. 130-146. In J. E. Alouf and J. H. Freer (ed.), The comprehensive sourcebook of bacterial protein toxins. Academic Press, Inc., New York, N.Y. 247. Lord, J. M., D. C. Smith, and L. M. Roberts. 1999. Toxin entry: how bacterial proteins get into mammalian cells. Cell. Microbiol. 1:85-91. [PubMed]. 247a. Madden, J. C., N. Ruiz, and M. Caparon. 2001. Cytolysin-mediated translocation (CMT): a functional equivalent of type III secretion in gram-positive bacteria. Cell 104:143-152. [PubMed]. 248. Madshus, I. H., H. Stenmark, K. Sandvig, and S. Olsnes. 1991. Entry of diphtheria toxin-protein A chimeras into cells. J. Biol. Chem. 266:17446-17453. [PubMed]. 249. Mahlandt, B. G., F. Klein, R. E. Lincoln, B. W. Haines, W. I. Jones, Jr., and R. H. Friedman. 1966. Evaluation of the immunogenicity of three components of anthrax toxin. J. Immunol. 96:727-733. [PubMed]. 250. Majoul, I., D. Ferrari, and H. D. Soling. 1997. Reduction of protein disulfide bonds in an oxidizing environment—the disulfide bridge of cholera toxin A-subunit is reduced in the endoplasmic reticulum. FEBS Lett. 401:104-108. [PubMed]. 251. Margulis, L., J. Z. Jorgensen, S. Dolan, R. Kolchinsky, F. A. Rainey, and S.-C. Lo. 1998. The Arthromitus stage of Bacillus cereus: intestinal symbionts of animals. Proc. Natl. Acad. Sci. USA 95:1236-1241. [PubMed]. 252a. Martinez, R. D., and T. D. Wilkins. 1992. Comparison of Clostridium sordellii toxin HT and LT with toxins A and B of Clostridium difficile. J. Med. Microbiol. 36:30-36. [PubMed]. 252. Marvaud, J.-C., T. Smith, M. L. Hale, M. R. Popoff, L. A. Smith, and B. G. Stiles. 2001. Clostridium perfringens iota-toxin: mapping of receptor binding and Ia docking domains on Ib. Infect. Immun. 69:2435-2441. [PubMed]. 253. Marvaud, J.-C., B. G. Stiles, A. Chenal, D. Gillet, M. Gibert, L. A. Smith, and M. R. Popoff. 2002. Clostridium perfringens iota toxin. Mapping of the Ia domain involved in docking with Ib and cellular internalization. J. Biol. Chem. 277:43659-43666. [PubMed]. 254. Matter, K., F. Dreyer, and K. Aktories. 1989. Actin involvement in exocytosis from PC12 cells: studies on the influence of botulinum C2 toxin on stimulated noradrenaline release. J. Neurochem. 52:370-376. [PubMed]. 254a. Matyas, G. R., A. M. Friedlander, G. M. Glenn, S. Little, J. Yu, and C. R. Alving. 2004. Needle-free skin patch vaccination method for anthrax. Infect. Immun. 72:1181-1183. [PubMed]. 255. Mauss, S., C. Chaponnier, I. Just, K. Aktories, and G. Gabbiani. 1990. ADP-ribosylation of actin isoforms by Clostridium botulinum C2 toxin and Clostridium perfringens iota toxin. Eur. J. Biochem. 194:237-241. [PubMed]. 256. Mauss, S., G. Koch, V. A. Kreye, and K. Aktories. 1989. Inhibition of the contraction of the isolated longitudinal muscle of the guinea-pig ileum by botulinum C2 toxin: evidence for a role of G/F-actin transition in smooth muscle contraction. Naunyn Schmiedeberg's Arch. Pharmacol. 340:345-351. 257. Maynard, J. A., C. B. Maassen, S. H. Leppla, K. Brasky, J. L. Patterson, B. L. Iverson, and G. Georgiou. 2002. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat. Biotechnol. 20:597-601. [PubMed]. 258. McDonel, J. L. 1986. Toxins of Clostridium perfringens types A, B, C, D and E, p. 477-517. In F. Dorner and J. Drews (ed.), Pharmacology of bacterial toxins. Pergamon Press, Inc., New York, N.Y. 259. McKillip, J. L. 2000. Prevalence and expression of enterotoxins in Bacillus cereus and other Bacillus spp., a literature review. Antonie Leeuwenhoek 77:393-399. [PubMed]. 260. Meer, R. R., and J. G. Songer. 1997. Multiplex polymerase chain reaction assay for genotyping Clostridium perfringens. Am. J. Vet. Res. 58:702-705. [PubMed]. 261. Mehra, V., H. Khanna, R. Chandra, and Y. Singh. 2001. Anthrax-toxin-mediated delivery of a 19 kDa antigen of Mycobacterium tuberculosis into the cytosol of mammalian cells. Biotechnol. Appl. Biochem. 33:71-74. [PubMed]. 262. Melamed, I., G. P. Downey, K. Aktories, and C. M. Roifman. 1991. Microfilament assembly is required for antigen-receptor-mediated activation of human B lymphocytes. J. Immunol. Methods 147:1139-1146. 263. Melamed, I., R. A. Franklin, and E. W. Gelfand. 1995. Microfilament assembly is required for anti-IgM dependent MAPK and p90rsk activation in human B lymphocytes. Biochem. Biophys. Res. Commun. 209:1102-1110. [PubMed]. 264. Melamed, I., and E. W. Gelfand. 1999. Microfilament assembly is involved in B-cell apoptosis. Cell Immunol. 194:136-142. [PubMed]. 265. Melamed, I., L. Stein, and C. M. Roifman. 1994. Epstein-Barr virus induces actin polymerization in human B cells. J. Immunol. 153:1998-2003. [PubMed]. 266. Melamed, I., C. E. Turner, K. Aktories, D. R. Kaplan, and E. W. Gelfand. 1995. Nerve growth factor triggers microfilament assembly and paxillin phosphorylation in human B lymphocytes. J. Exp. Med. 181:1071-1079. [PubMed]. 267. Menard, A., K. D. Altendorf, D. D. Breves, M. Mock, and C. Montecucco. 1996. The vacuolar ATPase proton pump is required for the cytotoxicity of Bacillus anthracis lethal toxin. FEBS Lett. 386:161-164. [PubMed]. 268. Menard, A., J. E. Papini, M. Mock, and C. Montecucco. 1996. The cytotoxic activity of Bacillus anthracis lethal factor is inhibited by leukotriene A4 hydrolase and metallopeptidase inhibitors. Biochem. J. 320:687-691. [PubMed]. 269. Miethke, T., C. Wahl, K. Heeg, B. Echtenacher, P. H. Krammer, and H. Wagner. 1992. T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor. J. Exp. Med. 175:91-98. [PubMed]. 270. Mignot, T., M. Mock, and A. Fouet. 2003. A plasmid-encoded regulator couples the synthesis of toxins and surface structures in Bacillus anthracis. Mol. Microbiol. 47:917-927. [PubMed]. 271. Mikesell, P., B. E. Ivins, J. D. Ristroph, and T. M. Dreier. 1983. Evidence for plasmid-mediated toxin production in Bacillus anthracis. Infect. Immun. 39:371-376. [PubMed]. 272. Miller, C. J., J. L. Elliott, and R. J. Collier. 1999. Anthrax protective antigen: prepore-to-pore conversion. Biochemistry 38:10432-10441. [PubMed]. 273. Milne, J. C., S. R. Blanke, P. C. Hanna, and R. J. Collier. 1995. Protective antigen- binding domain of anthrax lethal factor mediates translocation of a heterologous protein fused to its amino- or carboxy-terminus. Mol. Microbiol. 15:661-666. [PubMed]. 274. Milne, J. C., and R. J. Collier. 1993. pH-dependent permeabilization of the plasma membrane of mammalian cells by anthrax protective antigen. Mol. Microbiol. 10:647-653. [PubMed]. 275. Milne, J. C., D. Furlong, P. C. Hanna, J. S. Wall, and R. J. Collier. 1994. Anthrax protective antigen forms oligomers during intoxication of mammalian cells. J. Biol. Chem. 269:20607-20612. [PubMed]. 276. Miyake, M., and I. Ohishi. 1987. Response of tissue-cultured cynomolgus monkey kidney cells to botulinum C2 toxin. Microb. Pathog. 3:279-286. [PubMed]. 277. Miyata, S., J. Minami, E. Tamai, O. Matsushita, S. Shimamota, and A. Okabe. 2002. Clostridium perfringens epsilon-toxin forms a heptameric pore within the detergent-insoluble microdomains of Madin-Darby canine kidney cells and rat synaptosomes. J. Biol. Chem. 277:39463-39468. [PubMed]. 278. Moayeri, M., D. Haines, H. A. Young, and S. H. Leppla. 2003. Bacillus anthracis lethal toxin induces TNF-α-independent hypoxia-mediated toxicity in mice. J. Clin. Investig. 112:670-682. [PubMed]. 279. Mock, M., and T. Mignot. 2003. Anthrax toxins and the host: a story of intimacy. Cell. Microbiol. 5:15-23. [PubMed]. 280. Mock, M., and B. P. Roques. 2002. Progress in rapid screening of Bacillus anthracis lethal factor activity. Proc. Natl. Acad. Sci. USA 99:6527-6529. [PubMed]. 281. Mogridge, J., K. Cunningham, and R. J. Collier. 2002. Stoichiometry of anthrax toxin complexes. Biochemistry 41:1079-1082. [PubMed]. 282. Mogridge, J., K. Cunningham, D. B. Lacy, M. Mourez, and R. J. Collier. 2002. The lethal and edema factors of anthrax toxin bind only to oligomeric forms of the protective antigen. Proc. Natl. Acad. Sci. USA 99:7045-7048. [PubMed]. 283. Mogridge, J., M. Mourez, and R. J. Collier. 2001. Involvement of domain 3 in oligomerization by the protective antigen moiety of anthrax toxin. J. Bacteriol. 183:2111-2116. [PubMed]. 284. Moriya, O., M. Matsui, M. Osorio, H. Miyazawa, C. M. Rice, S. M. Feinstone, S. H. Leppla, J. M. Keith, and T. Akatsuka. 2002. Induction of hepatitis C virus-specific cytotoxic T lymphocytes in mice by immunization with dendritic cells treated with an anthrax toxin fusion protein. Vaccine 20:789-796. 285. Mourez, M., R. S. Kane, J. Mogridge, S. Metallo, P. Deschatelets, B. R. Sellman, G. M. Whitesides, and R. J. Collier. 2001. Designing a polyvalent inhibitor of anthrax toxin. Nat. Biotechnol. 19:958-961. [PubMed]. 285a. Mourez, M., M. Yan, D. B. Lacy, L. Dillon, L. Bentsen, A. Marpoe, C. Maurin, E. Hotze, D. Wigelsworth, R.-A. Pimental, J. D. Ballard, R. J. Collier, and R. K. Tweten. 2003. Mapping dominant-negative mutations of anthrax protective antigen by scanning mutagenesis. Proc. Natl. Acad. Sci. USA 100:13803-13808. [PubMed]. 286. Munier, H., A. Bouhss, A. M. Gilles, E. Krin, P. Glaser, A. Danchin, and O. Barzu. 1993. Structural flexibility of the calmodulin-binding locus in Bordetella pertussis adenylate cyclase. Reconstitution of catalytically active species from fragments or inactive forms of the enzyme. Eur. J. Biochem. 217:581-586. [PubMed]. 287. Nagahama, M., A. Kihara, T. Miyawaki, M. Mukai, Y. Sakaguchi, S. Ochi, and J. Sakurai. 2000. Characterization of the enzymatic component of Clostridium perfringens iota-toxin. J. Bacteriol. 182:2096-2103. [PubMed]. 288. Nagahama, M., K. Nagayasu, K. Kobayashi, and J. Sakurai. 2002. Binding component of Clostridium perfringens iota-toxin induces endocytosis in Vero cells. Infect. Immun. 70:1909-1914. [PubMed]. 289. Nakamura, S., T. Serikawa, K. Yamakawa, S. Nishida, S. Kozaki, and G. Sakaguchi. 1978. Sporulation and C2 toxin production by Clostridium botulinum type C strains producing no C1 toxin. Microbiol. Immunol. 22:591-596. [PubMed]. 290. Nassi, S., R. J. Collier, and A. Finkelstein. 2002. PA 63 channel of anthrax toxin: an extended β-barrel. Biochemistry 41:1445-1450. [PubMed]. 291. Nilius, B., T. Voets, J. Prenen, H. Barth, K. Aktories, K. Kaibuchi, G. Droogmans, and J. Eggermont. 1999. Role of Rho and Rho kinase in the activation of volume- regulated anion channels in bovine endothelial cells. J. Physiol. 516:67-74. [PubMed]. 292. Norgauer, J., I. Just, K. Aktories, and L. A. Sklar. 1989. Influence of botulinum C2 toxin on F-actin and N-formyl peptide receptor dynamics in human neutrophils. J. Cell Biol. 109:1133-1140. [PubMed]. 293. Norgauer, J., E. Kownatzki, R. Seifert, and K. Aktories. 1988. Botulinum C2 toxin ADP-ribosylates actin and enhances O 2 production and secretion but inhibits migration of activated human neutrophils. J. Clin. Investig. 82:1376-1382. [PubMed]. 294. Novak, J. M., M. P. Stein, S. F. Little, S. H. Leppla, and A. M. Friedlander. 1992. Functional characterization of protease-treated Bacillus anthracis protective antigen. J. Biol. Chem. 267:17186-17193. [PubMed]. 295. Oakley, C., and G. Warrack. 1953. Routine typing of Clostridium welchii. J. Hyg. (Cambridge) 51:102-107. 296. O'Brien, J., A. Friedlander, T. Dreier, J. Ezzell, and S. Leppla. 1985. Effects of anthrax toxin components on human neutrophils. Infect. Immun. 47:306-310. [PubMed]. 297. Ohishi, I. 1983. Lethal and vascular permeability activities of botulinum C2 toxin induced by separate injections of the two toxin components. Infect. Immun. 40:336-339. [PubMed]. 298. Ohishi, I. 1983. Response of mouse intestinal loop to botulinum C2 toxin: enterotoxic activity induced by cooperation of nonlinked protein components. Infect. Immun. 40:691-695. [PubMed]. 299. Ohishi, I. 1987. Activation of botulinum C2 toxin by trypsin. Infect. Immun. 55:1461-1465. [PubMed]. 300. Ohishi, I. 2000. Structure and function of actin-adenosine-diphosphate-ribosylating toxins, p. 253-273. In K. Aktories and I. Just. (ed.), Bacterial protein toxins. Springer Verlag KG, Berlin, Germany. 301. Ohishi, I., and Y. Hama. 1992. Purification and characterization of heterologous component IIs of botulinum C2 toxin. Microbiol. Immunol. 36:221-229. [PubMed]. 302. Ohishi, I., M. Iwasaki, and G. Sakaguchi. 1980. Purification and characterization of two components of botulinum C2 toxin. Infect. Immun. 30:668-673. [PubMed]. 303. Ohishi, I., M. Iwasaki, and G. Sakaguchi. 1980. Vascular permeability activity of botulinum C2 toxin elicited by cooperation of two dissimilar protein components. Infect. Immun. 31:890-895. 304. Ohishi, I., and M. Miyake. 1985. Binding of the two components of C2 toxin to epithelial cells and brush borders of mouse intestine. Infect. Immun. 48:769-775. [PubMed]. 305. Ohishi, I., M. Miyake, H. Ogura, and S. Nakamura. 1984. Cytopathic effect of botulinum C2 toxin on tissue-culture cells. FEMS Microbiol. Lett. 23:281-284. 306. Ohishi, I., and Y. Odagiri. 1984. Histopathological effect of botulinum C2 toxin on mouse intestines. Infect. Immun. 43:54-58. [PubMed]. 307. Ohishi, I., and Y. Okada. 1986. Heterogeneities of two components of C2 toxin produced by Clostridium botulinum types C and D. J. Gen. Microbiol. 132:125-131. 308. Ohishi, I., and G. Sakaguchi. 1980. Oral toxicities of Clostridium botulinum type C and D toxins of different molecular sizes. Infect. Immun. 28:303-309. [PubMed]. 309. Ohishi, I., and G. Sakaguchi. 1982. Production of C2 toxin by Clostridium botulinum types C and D as determined by its vascular permeability activity. Infect. Immun. 35:1-4. [PubMed]. 310. Ohishi, I., and S. Tsuyama. 1986. ADP-ribosylation of nonmuscle actin with component I of C2 toxin. Biochem. Biophys. Res. Commun. 136:802-806. [PubMed]. 311. Ohishi, I., and A. Yanagimoto. 1992. Visualizations of binding and internalization of two nonlinked protein components of botulinum C2 toxin in tissue culture cells. Infect. Immun. 60:4648-4655. [PubMed]. 312. Okinaka, R. T., K. Cloud, O. Hampton, A. R. Hoffmaster, K. K. Hill, P. Keim, T. M. Koehler, G. Lamke, S. Kumano, J. Mahillon, D. Manter, Y. Martinez, D. Ricke, R. Svensson, and P. J. Jackson. 1999. Sequence and organization of pXO1, the large Bacillus anthracis plasmid harboring the anthrax toxin genes. J. Bacteriol. 181:6509-6515. [PubMed]. 313. Orlandi, P. A., P. K. Curran, and P. H. Fishman. 1993. Brefeldin A blocks the response of cultured cells to cholera toxin. Implications for intracellular trafficking in toxin action. J. Biol. Chem. 268:12010-12016. [PubMed]. 313a. Panchal, R. G., A. R. Hermone, T. L. Nguyen, T. Y. Wong, R. Schwarzenbacher, J. Schmidt, D. Lane, C. McGrath, B. E. Turk, J. Burnett, M. J. Aman, S. Little, E. A. Sausville, D. W. Zaharevitz, L. C. Cantley, R. C. Liddington, R. Gusssio, and S. Bavari. 2004. Identification of small molecule inhibitors of anthrax lethal factor. Nat. Struct. Mol. Biol. 11:67-72. [PubMed]. 314. Pannifer, A. D., T. Y. Wong, R. Schwarzenbacher, M. Renatus, C. Petosa, J. Bienkowska, D. B. Lacy, R. J. Collier, S. Park, S. H. Leppla, P. Hanna, and R. C. Liddington. 2001. Crystal structure of the anthrax lethal factor. Nature 414:229-233. [PubMed]. 315. Pannucci, J., R. T. Okinaka, R. Sabin, and C. R. Kuske. 2002. Bacillus anthracis pXO1 plasmid sequence conservation among closely related bacterial species. J. Bacteriol. 184:134-141. [PubMed]. 316. Park, J. M., F. R. Greten, A.-W. Li, and M. Karin. 2002. Macrophage apoptosis by anthrax lethal factor through p38 MAP kinase inhibition. Science 297:2048-2051. [PubMed]. 317. Pastan, I., V. Chaudhary, and D. J. FitzGerald. 1992. Recombinant toxins as novel therapeutic agents. Annu. Rev. Biochem. 61:331-354. [PubMed]. 318. Pasteur, L. 1881. De l'attenuation des virus et de leur retour a la virulence. C. R. Acad. Sci. Agric. Bulg. 92:429-435. 319. Patton, N. M., H. T. Holmes, R. J. Riggs, and P. R. Cheeke. 1978. Enterotoxemia in rabbits. Lab. Anim. Sci. 28:536-540. [PubMed]. 320. Peeters, J. E., R. Geeroms, R. J. Carman, and T. D. Wilkins. 1986. Significance of Clostridium spiroforme in the enteritis-complex of commercial rabbits. Vet. Microbiol. 12:25-31. [PubMed]. 321. Pellizzari, R., C. Guidi-Rontani, G. Vitale, M. Mock, and C. Montecucco. 1999. Anthrax lethal factor cleaves MKK3 in macrophages and inhibits the LPS/IFNgamma-induced release of NO and TNFalpha. FEBS Lett. 462:199-204. [PubMed]. 322. Perelle, S., M. Domenighini, and M. R. Popoff. 1996. Evidence that Arg-295, Glu-378, and Glu-380 are active-site residues of the ADP-ribosyltransferase activity of iota toxin. FEBS Lett. 395:191-194. [PubMed]. 323. Perelle, S., M. Gibert, P. Boquet, and M. R. Popoff. 1993. Characterization of Clostridium perfringens iota-toxin genes and expression in Escherichia coli. Infect. Immun. 61:5147-5156. [PubMed]. 324. Perelle, S., M. Gibert, P. Bourlioux, G. Corthier, and M. R. Popoff. 1997. Production of a complete binary toxin (actin-specific ADP-ribosyltransferase) by Clostridium difficile CD196. Infect. Immun. 65:1402-1407. [PubMed]. 325. Perelle, S., S. Scalzo, S. Kochi, M. Mock, and M. R. Popoff. 1997. Immunological and functional comparison between Clostridium perfringens iota toxin, C. spiroforme toxin, and anthrax toxins. FEMS Microbiol. Lett. 146:117-121. [PubMed]. 326. Petosa, C., R. J. Collier, K. R. Klimpel, S. H. Leppla, and R. C. Liddington. 1997. Crystal structure of the anthrax toxin protective antigen. Nature 385:833-838. [PubMed]. 327. Pezard, C., P. Berche, and M. Mock. 1991. Contribution of individual toxin components to virulence of Bacillus anthracis. Infect. Immun. 59:3472-3477. [PubMed]. 328. Pezard, C., M. Weber, J. C. Sirard, P. Berche, and M. Mock. 1995. Protective immunity induced by Bacillus anthracis toxin-deficient strains. Infect. Immun. 63:1369-1372. [PubMed]. 329. Pitt, M. L., S. F. Little, B. E. Ivins, P. Fellows, J. Barth, J. Hewetson, P. Gibbs, M. Dertzbaugh, and A. M. Friedlander. 2001. In vitro correlate of immunity in a rabbit model of inhalational anthrax. Vaccine 19:4768-4773. [PubMed]. 330. Pittman, P. R., G. Kim-Ahn, D. Y. Pifat, K. Coonan, P. Gibbs, S. Little, J. G. Pace- Templeton, R. Myers, G. W. Parker, and A. M. Friedlander. 2002. Anthrax vaccine: immunogenicity and safety of a dose-reduction, route-change comparison study in humans. Vaccine 20:1412-1420. [PubMed]. 330a. Pizza, M., V. Masignani, and R. Rappuoli. 1999. Molecular, functional and evolutionary aspects of ADP-ribosylating toxins, p. 45-72. In J. E. Alouf and J. H. Freer (ed.), The comprehensive sourcebook of bacterial protein toxins. Academic Press, Inc., New York, N.Y. 331. Popoff, M. R. 2000. Molecular biology of actin-ADP-ribosylating toxins, p. 275-306. In K. Aktories and I. Just (ed.), Handbook of experimental pharmacology, vol. 145. Bacterial protein toxins. Springer-Verlag KG, Berlin, Germany. 332. Popoff, M. R., and P. Boquet. 1988. Clostridium spiroforme toxin is a binary toxin which ADP-ribosylates cellular actin. Biochem. Biophys. Res. Commun. 152:1361-1368. [PubMed]. 332a. Popoff, M. R., and J. C. Marvaud. 1999. Structural and genomic features of clostridial neurotoxins, p. 174-201. In J. E. Alouf and J. H. Freer (ed.), The comprehensive sourcebook of bacterial protein toxins. Academic Press, Inc., New York, N.Y. 333. Popoff, M. R., F. W. Milward, B. Bancillon, and P. Boquet. 1989. Purification of the Clostridium spiroforme binary toxin and activity of the toxin on HEp-2 cells. Infect. Immun. 57:2462-2469. [PubMed]. 334. Popoff, M. R., E. J. Rubin, D. M. Gill, and P. Boquet. 1988. Actin-specific ADP-ribosyltransferase produced by a Clostridium difficile strain. Infect. Immun. 56:2299-2306. [PubMed]. 335. Popov, S. G., R. Villasmil, J. Bernardi, E. Grene, J. Cardwell, T. Popova, A. Wu, D. Alibek, C. Bailey, and K. Alibek. 2002. Effect of Bacillus anthracis lethal toxin on human peripheral blood mononuclear cells. FEBS Lett. 527:211-215. [PubMed]. 336. Popov, S. G., R. Villasmil, J. Bernardi, E. Grene, J. Cardwell, A. Wu, D. Alibek, C. Bailey, and K. Alibek. 2002. Lethal toxin of Bacillus anthracis causes apoptosis of macrophages. Biochem. Biophys. Res. Commun. 293:349-355. [PubMed]. 337. Pratt, W. B., and D. O. Toft. 2003. Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp. Biol. Med. 228:111-133. 338. Prekeris, R., M. W. Mayhew, J. B. Cooper, and D. M. Terrian. 1996. Identification and localization of an actin-binding motif that is unique to the epsilon isoform of protein kinase C and participates in the regulation of synaptic function. J. Cell Biol. 132:77-90. [PubMed]. 339. Prepens, U., H. Barth, J. Wilting, and K. Aktories. 1998. Influence of Clostridium botulinum C2 toxin on Fc RI-mediated secretion and tyrosine phosphorylation in RBL cells. Naunyn-Schmiedeberg's Arch. Pharmacol. 357:323-330. [PubMed]. 340. Prepens, U., I. Just, F. Hofmann, and K. Aktories. 1997. ADP-ribosylating and glucosylating toxins as tools to study secretion in RBL cells. Adv. Exp. Med. Biol. 419:349-353. [PubMed]. 341. Prepens, U., I. Just, C. von Eichel-Streiber, and K. Aktories. 1996. Inhibition of Fc RI-mediated activation of rat basophilic leukemia cells by Clostridium difficile toxin B (monoglucosyltransferase). J. Biol. Chem. 271:7324-7329. [PubMed]. 341a. Prevost, G. 1999. The bi-component staphylococcal leucocidins and γ-haemolysins (toxins), p. 402-418. In J. E. Alouf and J. H. Freer (ed.), The comprehensive sourcebook of bacterial protein toxins. Academic Press, Inc., New York, N.Y. 342. Price, L. B., M. Hugh-Jones, P. J. Jackson, and P. Keim. 1999. Genetic diversity in the protective antigen gene of Bacillus anthracis. J. Bacteriol. 181:2358-2362. [PubMed]. 343. Price, B. M., A. L. Liner, S. Park, S. H. Leppla, A. Mateczun, and D. R. Galloway. 2001. Protection against anthrax lethal toxin challenge by genetic immunization with a plasmid encoding the lethal factor protein. Infect. Immun. 69:4509-4515. [PubMed]. 344. Prince, A. S. 2003. The host response to anthrax lethal toxin: unexpected observations. J. Clin. Investig. 112:656-658. [PubMed]. 345. Quinn, C. P., Y. Singh, K. R. Klimpel, and S. H. Leppla. 1991. Functional mapping of anthrax toxin lethal factor by in-frame insertion mutagenesis. J. Biol. Chem. 266:20124-20130. [PubMed]. 346. Quintiliani, R., Jr., and R. Quintiliani. 2003. Inhalational anthrax and bioterrorism. Curr. Opin. Pulm. Med. 9:221-226. [PubMed]. 347. Radke, J., K. J. Pederson, and J. T. Barbieri. 1999. Pseudomonas aeruginosa exoenzyme S is a biglutamic acid ADP ribosyltransferase. Infect. Immun. 67:1508-1510. [PubMed]. 347a. Rasko, D. A., J. Ravel, O. A. Okstad, E. Helgason, R. Z. Cer, L. Jiang, K. A. Shores, D. E. Fouts, N. J. Tourasse, S. V. Angiuoli, J. Kolonay, W. C. Nelson, A. B. Kolsto, C. M. Fraser, and T. D. Read. 2004. The genome sequence of Bacillus cereus ATCC 10987 reveals metabolic adaptations and a large plasmid related to Bacillus anthracis pXO1. Nucleic Acids Res. 32:977-988. [PubMed]. 348. Ratts, R., H. Zeng, E. A. Berg, C. Blue, M. E. McComb, C. E. Costello, J. C. vanderSpeck, and J. R. Murphy. 2003. The cytosolic entry of diphtheria toxin catalytic domain requires a host cell cytosolic translocation factor complex. J. Cell Biol. 160:1139-1150. [PubMed]. 349. Read, T. D., S. N. Peterson, N. Tourasse, L. W. Baillie, I. T. Paulsen, K. E. Nelson, H. Tettelin, D. E. Fouts, J. A. Eisen, S. R. Gill, et. al. 2003. The genome sequence of Bacillus anthracis Ames and comparison to closely related bacteria. Nature 423:81-86. [PubMed]. 350. Reuner, K. H., P. Presek, C. B. Boschek, and K. Aktories. 1987. Botulinum C2 toxin ADP-ribosylates actin and disorganizes the microfilament network in intact cells. Eur. J. Cell Biol. 43:134-140. [PubMed]. 351. Reuner, K. H., K. Schlegel, I. Just, K. Aktories, and N. Katz. 1991. Autoregulatory control of actin synthesis in cultured rat hepatocytes. FEBS Lett. 286:100-104. [PubMed]. 352. Reuner, K. H., A. van der Does, P. Dunker, I. Just, K. Aktories, and N. Katz. 1996. Microinjection of ADP-ribosylated actin inhibits actin synthesis in hepatocyte-hepatoma hybrid cells. Biochem. J. 319:843-849. [PubMed]. 353. Reuner, K. H., M. Wiederhold, P. Dunker, I. Just, R. M. Bohle, M. Kroger, and N. Katz. 1995. Autoregulation of actin synthesis in hepatocytes by transcriptional and posttranscriptional mechanisms. Eur. J. Biochem. 230:32-37. [PubMed]. 354. Reuner, K. H., M. Wiederhold, K. Schlegel, I. Just, and N. Katz. 1995. Autoregulation of actin synthesis by physiological alterations of the G-actin level in hepatocytes. Eur. J. Clin. Chem. Clin. Biochem. 33:569-574. [PubMed]. 354a. Reuveny, S., M. D. White, Y. Y. Adar, Y. Kafri, Z. Altboum, Y. Gozes, D. Kobiler, A. Shafferman, and B. Velan. 2001. Search for correlates of protective immunity conferred by anthrax vaccine. Infect. Immun. 69:2888-2893. [PubMed]. 355. Rhie, G.-E., M. H. Roehrl, M. Mourez, R. J. Collier, J. J. Mekalanos, and J. Y. Wang. 2003. A dually active anthrax vaccine that confers protection against both bacilli and toxins. Proc. Natl. Acad. Sci. USA 100:10925-10930. [PubMed]. 356. Richard, J. F., G. Mainguy, M. Gibert, J. C. Marvaud, B. G. Stiles, and M. R. Popoff. 2002. Transcytosis of iota-toxin across polarized CaCo-2 cells. Mol. Microbiol. 43:907-917. [PubMed]. 357. Richardson, J. S. 1977. β-sheet topology and the relatedness of proteins. Nature 268:495-500. [PubMed]. 358. Riese, M. J., and J. T. Barbieri. 2002. Membrane localization contributes to the in vivo ADP-ribosylation of Ras by Pseudomonas aeruginosa ExoS. Infect. Immun. 70:2230-2232. [PubMed]. 359. Rivera, V. R., G. A. Merrill, J. A. White, and M. A. Poli. 2003. An enzymatic electrochemiluminescence assay for the lethal factor of anthrax. Anal. Biochem. 321:125-130. [PubMed]. 360. Robertson, D. L., M. T. Tippetts, and S. H. Leppla. 1988. Nucleotide sequence of the Bacillus anthracis edema factor gene ( cya): a calmodulin-dependent adenylate cyclase. Gene 73:363-371. [PubMed]. 361. Rosovitz, M. J., P. Schuck, M. Varughese, A. P. Chopra, V. Mehra, Y. Singh, L. M. McGinnis, and S. H. Leppla. 2003. Alanine scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody. J. Biol. Chem. 278:30936-30944. [PubMed]. 362. Ross, H. E., M. E. Warren, and J. M. Barnes. 1949. Clostridium welchii iota toxin: its activation by trypsin. J. Gen. Microbiol. 3:148-152. 363. Rubin, E. J., D. M. Gill, P. Boquet, and M. R. Popoff. 1988. Functional modification of a 21-kilodalton G protein when ADP-ribosylated by exoenzyme C3 of Clostridium botulinum. Mol. Cell Biol. 8:418-426. [PubMed]. 364. Ryu, S., and R. G. Labbe. 1989. Coat and enterotoxin-related proteins in Clostridium perfringens spores. J. Gen. Microbiol. 135:3109-3118. [PubMed]. 365. Sakai, T., S. Yamashina, and S. Ohnishi. 1991. Microtubule-disrupting drugs blocked delivery of endocytosed transferrin to the cytocenter, but did not affect return of transferrin to plasma membrane. J. Biochem. (Tokyo) 109:528-533. [PubMed]. 366. Sakr, S., R. J. Eddy, H. Barth, F. Wang, S. Greenberg, F. R. Maxfield, and I. Tabas. 2001. The uptake and degradation of matrix-bound lipoproteins by macrophages require an intact actin cytoskeleton, Rho family GTPases, and myosin ATPase activity. J. Biol. Chem. 276:37649-37658. [PubMed]. 367. Sakurai, J., and K. Kobayashi. 1995. Lethal and dermonecrotic activities of Clostridium perfringens iota toxin: biological activities induced by cooperation of two nonlinked components. Microbiol. Immunol. 39:249-253. [PubMed]. 368. Sakurai, J., M. Nagahama, J. Hisatsune, N. Katunuma, and H. Tsuge. 2003. Clostridium perfringens iota-toxin, ADP-ribosyltransferase: structure and mechanism of action. Adv. Enzyme Regul. 43:361-377. [PubMed]. 369. Salles, I. I., A. E. Tucker, D. E. Voth, and J. D. Ballard. 2003. Toxin-induced resistance in Bacillus anthracis lethal toxin-treated macrophages. Proc. Natl. Acad. Sci. USA 100:12426-12431. [PubMed]. 370. Sandvig, K., and B. Van Deurs. 1996. Endocytosis, intracellular transport, and cytotoxic action of shiga toxin and ricin. Physiol. Rev. 76:949-966. [PubMed]. 371. Sarker, M. R., U. Singh, and B. A. McClane. 2000. An update on Clostridium perfringens enterotoxin. J. Nat. Toxins 9:251-266. [PubMed]. 372. Schering, B., M. Barmann, G. S. Chhatwal, U. Geipel, and K. Aktories. 1988. ADP-ribosylation of skeletal muscle and non-muscle actin by Clostridium perfringens iota toxin. Eur. J. Biochem. 171:225-229. [PubMed]. 373. Schmid, A., R. Benz, I. Just, and K. Aktories. 1994. Interaction of Clostridium botulinum C2 toxin with lipid bilayer membranes: formation of cation-selective channels and inhibition of channel function by chloroquine and peptides. J. Biol. Chem. 269:16706-16711. [PubMed]. 374. Schmid, G., A. Schürmann, C. Huppertz, F. Hofmann, K. Aktories, and H.-G. Joost. 1998. Inhibition of insulin-stimulated glucose transport in 3T3-L1 cells by Clostridium difficile toxin B, Clostridium sordellii lethal toxin, and Clostridium botulinum C2 toxin. Naunyn-Schmiedeberg's Arch. Pharmacol. 357:385-392. [PubMed]. 375. Schmidt, J. J., and R. G. Stafford. 2003. Fluorigenic substrates for the protease activities of botulinum neurotoxins, serotypes A, B, and F. Appl. Environ. Microbiol. 69:297-303. [PubMed]. 376. Schneerson, R., J. Kubler-Kielb, T. Y. Liu, Z. D. Dai, S. H. Leppla, A. Yergey, P. Backlund, J. Shiloach, F. Majadly, and J. B. Robbins. 2003. Poly(γ-d-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: a potential addition to the anthrax vaccine. Proc. Natl. Acad. Sci. USA 100:8945-8950. [PubMed]. 377. Schnittler, H.-J., S. W. Schneider, H. Raifer, F. Luo, P. Dieterich, I. Just, and K. Aktories. 2001. Role of actin filaments in endothelial cell-cell adhesion and membrane stability under fluid shear stress. Pflügers Arch.-Eur. J. Physiol. 442:675-687. 378. Schuch, R., D. Nelson, and V. A. Fischetti. 2002. A bacteriolytic agent that detects and kills Bacillus anthracis. Nature 418:884-888. [PubMed]. 379. Scobie, H. M., G. J. Rainey, K. A. Bradley, and J. A. Young. 2003. Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proc. Natl. Acad. Sci. USA 100:5170-5174. [PubMed]. 380. Sekine, A., M. Fujiwara, and S. Narumiya. 1989. Asparagine residue in the ρ gene product is the modification site for botulinum ADP-ribosyltransferase. J. Biol. Chem. 264:8602-8605. [PubMed]. 381. Sellman, B. R., M. Mourez, and R. J. Collier. 2001. Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax. Science 292:695-697. [PubMed]. 382. Sellman, B. R., S. Nassi, and R. J. Collier. 2001. Point mutations in anthrax protective antigen that block translocation. J. Biol. Chem. 276:8371-8376. [PubMed]. 383. Sharma, M., H. Khanna, N. Arora, and Y. Singh. 2000. Anthrax toxin-mediated delivery of cholera toxin-A subunit into the cytosol of mammalian cells. Biotechnol. Appl. Biochem. 32:69-72. [PubMed]. 384. Shen, Y., Y. S. Lee, S. Soelaiman, P. Bergson, D. Lu, A. Chen, K. Beckingham, Z. Grabarek, M. Mrksich, and W. J. Tang. 2002. Physiological calcium concentrations regulate calmodulin binding and catalysis of adenylyl cyclase exotoxins. EMBO J. 21:6721-6732. [PubMed]. 384a. Shen, Y., N. L. Zhukovskaya, M. I. Zimmer, S. Soelaiman, P. Bergson, C. R. Wang, C. S. Gibbs, and W. J. Tang. 2004. Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection. Proc. Natl. Acad. Sci. USA 101:3242-3247. [PubMed]. 385. Shimizu, T., K. Ohtani, H. Hirakawa, K. Ohshima, A. Yamashita, T. Shiba, N. Ogasawara, M. Hattori, S. Kuhara, and H. Hayashi. 2002. Complete genome sequence of Clostridium perfringens, an anaerobic flesh-eater. Proc. Natl. Acad. Sci. USA 99:996-1001. [PubMed]. 386. Shin, S., G. H. Hur, Y. B. Kim, K. J. Park, Y. M. Park, and W. S. Lee. 2000. Intracellular calcium antagonist protects cultured peritoneal macrophages against anthrax lethal toxin-induced cytotoxicity. Cell Biol. Toxicol. 16:137-144. [PubMed]. 387. Sibelius, U., K. Hattar, A. Schenkel, T. Noll, E. Csernok, W. L. Gross, W. J. Mayet, H. M. Piper, W. Seeger, and F. Grimminger. 1998. Wegener's granulomatosis: anti-proteinase 3 antibodies are potent inductors of human endothelial cell signaling and leakage response. J. Exp. Med. 187:497-503. [PubMed]. 388. Simons, K., and R. Ehehalt. 2002. Cholesterol, lipid rafts, and disease. J. Clin. Investig. 110:597-603. [PubMed]. 389. Simpson, L. L. 1981. The origin, structure, and pharmacological activity of botulinum toxin. Pharmacol. Rev. 33:155-187. [PubMed]. 390. Simpson, L. L. 1982. A comparison of the pharmacological properties of Clostridium botulinum type C1 and C2 toxins. J. Pharmacol. Exp. Ther. 223:695-701. [PubMed]. 391. Simpson, L. L. 1984. Molecular basis for the pharmacological actions of Clostridium botulinum type C2 toxin. J. Pharmacol. Exp. Ther. 230:665-669. [PubMed]. 392. Simpson, L. L. 1989. The binary toxin produced by Clostridium botulinum enters cells by receptor-mediated endocytosis to exert its pharmacologic effects. J. Pharmacol. Exp. Ther. 251:1223-1228. [PubMed]. 393. Simpson, L. L., B. G. Stiles, H. H. Zepeda, and T. D. Wilkins. 1987. Molecular basis for the pathological actions of Clostridium perfringens iota toxin. Infect. Immun. 55:118-122. [PubMed]. 394. Simpson, L. L., B. G. Stiles, H. Zepeda, and T. D. Wilkins. 1989. Production by Clostridium spiroforme of an iotalike toxin that possesses mono(ADP-ribosyl)transferase activity: identification of a novel class of ADP-ribosyltransferases. Infect. Immun. 57:255-261. [PubMed]. 395. Singh, A., V. Chauhan, A. Sodhi, and R. Bhatnagar. 2002. Asp 187 and Phe 190 residues in lethal factor are required for the expression of anthrax lethal toxin activity. FEMS Microbiol. Lett. 212:183-186. [PubMed]. 396. Singh, S., N. Ahuja, V. Chauhan, E. Rajasekaran, S. Mohsin Waheed, R. Bhat, and R. Bhatnagar. 2002. Gln277 and Phe554 residues are involved in thermal inactivation of protective antigen of Bacillus anthracis. Biochem. Biophys. Res. Commun. 296:1058-1062. [PubMed]. 397. Singh, Y., V. K. Chaudhary, and S. H. Leppla. 1989. A deleted variant of Bacillus anthracis protective antigen is non-toxic and blocks anthrax toxin action in vivo. J. Biol. Chem. 264:19103-19107. [PubMed]. 398. Singh, Y., B. E. Ivins, and S. H. Leppla. 1998. Study of immunization against anthrax with the purified recombinant protective antigen of Bacillus anthracis. Infect. Immun. 66:3447-3448. [PubMed]. 399. Singh, Y., H. Khanna, A. P. Chopra, and V. Mehra. 2001. A dominant negative mutant of Bacillus anthracis protective antigen inhibits toxin action in vivo. J. Biol. Chem. 276:22090-22094. [PubMed]. 400. Singh, Y., K. R. Klimpel, S. Goel, P. K. Swain, and S. H. Leppla. 1999. Oligomerization of anthrax toxin protective antigen and binding of lethal factor during endocytic uptake into mammalian cells. Infect. Immun. 67:1853-1859. [PubMed]. 401. Singh, Y., K. R. Klimpel, C. P. Quinn, V. K. Chaudhary, and S. H. Leppla. 1991. The carboxyl-terminal end of protective antigen is required for receptor binding and anthrax toxin activity. J. Biol. Chem. 266:15493-15497. [PubMed]. 402. Singh, Y., S. H. Leppla, R. Bhatnagar, and A. M. Friedlander. 1989. Internalization and processing of Bacillus anthracis lethal toxin by toxin-sensitive and -resistant cells. J. Biol. Chem. 264:11099-11102. [PubMed]. 403. Sirard, J.-C., M. Weber, E. Duflot, M. R. Popoff, and M. Mock. 1997. A recombinant Bacillus anthracis strain producing the Clostridium perfringens Ib component induces protection against iota toxins. Infect. Immun. 65:2029-2033. [PubMed]. 404. Sixma, T. K., S. E. Pronk, K. H. Kalk, E. S. Wartna, B. A. M. van Zanten, B. Witholt, and W. G. Hol. 1991. Crystal structure of a cholera toxin-related heat-labile enterotoxin from E. coli. Nature 351:371-377. [PubMed]. 405. Skalhegg, B. S., B. F. Landmark, S. O. Doskeland, V. Hansson, T. Lea, and T. Jahnsen. 1992. Cyclic AMP-dependent protein kinase type I mediates the inhibitory effects of 3′,5′-cyclic adenosine monophosphate on cell replication in human T lymphocytes. J. Biol. Chem. 267:15707-15714. [PubMed]. 406. Sklyarova, T., V. Kostyukovski, V. Sharov, V. Prisyazhnoy, and O. Denisenko. 1995. Alterations in protein synthesis induced by C2 toxin in 3T3 cells. FEBS Lett. 363:273-276. [PubMed]. 407. Smith, H. 2002. Discovery of the anthrax toxin: the beginning of studies of virulence determinants regulated in vivo. Int. J. Med. Microbiol. 291:411-417. [PubMed]. 408. Smith, H., A. E. Williams, J. H. Pearce, J. Keppie, P. W. Harris-Smith, R. B. Fitsgeorge, and K. Witt. 1956. The chemical basis of the virulence of Bacillus anthracis. VII. Two components of the anthrax toxin: their relationship to known immunizing aggressins. Br. J. Exp. Pathol. 37:263-271. [PubMed]. 409. Soelaiman, S., B. Q. Wei, P. Bergson, Y. S. Lee, Y. Shen, M. Mrksich, B. K. Shoichet, and W. J. Tang. 2003. Structure-based inhibitor discovery against adenylyl cyclase toxins from pathogenic bacteria that cause anthrax and whooping cough. J. Biol. Chem. 278:25990-25997. [PubMed]. 410. Song, L., M. R. Hobaugh, C. Shustak, S. Cheley, H. Bayley, and J. E. Gouaux. 1996. Structure of staphylococcal alpha-hemolysin, a heptameric transmembrane pore. Science 274:1859-1866. [PubMed]. 411. Songer, J. G. 1996. Clostridial enteric diseases of domestic animals. Clin. Microbiol. Rev. 9:216-234. [PubMed]. 412. Songer, J. G., and R. M. Meer. 1996. Genotyping of Clostridium perfringens by polymerase chain reaction is a useful adjunct to diagnosis of clostridial enteric disease in animals. Anaerobe 2:197-203. 413. Stanley, J. L., and H. Smith. 1961. Purification of factor I and recognition of a third factor of the anthrax toxin. J. Gen. Microbiol. 26:49-66. [PubMed]. 414. St. Croix, B., C. Rago, V. Velculescu, G. Traverso, K. E. Romans, E. Montgomery, A. Lal, G. J. Riggins, C. Lengauer, B. Vogelstein, and K. W. Kinzler. 2000. Genes expressed in human tumor endothelium. Science 289:1197-1202. [PubMed]. 415. Stein, P. E., A. Boodhoo, G. D. Armstrong, S. A. Cockle, M. H. Klein, and R. J. Read 1994. The crystal structure of pertussis toxin. Structure 2:45-57. [PubMed]. 416. Sterne, M. 1939. The use of anthrax vaccines prepared from avirulent (unencapsulated) variants of Bacillus anthracis. Oderstepoort J. Vet. Sci. Anim. Ind. 13:307-312. 417. Stiles, B. G. 1987. Purification and characterization of Clostridium perfringens iota toxin. Ph.D. thesis, Virginia Polytechnic Institute and State University, Blacksburg. 418. Stiles, B. G., D. Blöcker, M. L. Hale, M. A. Guetthoff, and H. Barth. 2002. Clostridium botulinum C2 toxin: binding studies with fluorescence-activated cytometry. Toxicon 40:1135-1140. [PubMed]. 419. Stiles, B. G., M. L. Hale, J.-C. Marvaud, and M. R. Popoff. 2000. Clostridium perfringens iota toxin: binding studies and characterization of cell surface receptor by fluorescence-activated cytometry. Infect. Immun. 68:3475-3484. [PubMed]. 420. Stiles, B. G., M. L. Hale, J.-C. Marvaud, and M. R. Popoff. 2002. Clostridium perfringens iota toxin: characterization of the cell-associated iota b complex. Biochem. J. 367:801-809. [PubMed]. 421. Stiles, B. G., and T. D. Wilkins. 1986. Clostridium perfringens iota toxin: synergism between two proteins. Toxicon 24:767-773. [PubMed]. 422. Stiles, B. G., and T. D. Wilkins. 1986. Purification and characterization of Clostridium perfringens iota toxin: dependence on two nonlinked proteins for biological activity. Infect. Immun. 54:683-688. [PubMed]. 423. Stoddart, B., and M. H. Wilcox. 2002. Clostridium difficile. Curr. Opin. Infect. Dis. 15:513-518. [PubMed]. 424. Strey, A., A. Janning, H. Barth, and V. Gerke. 2002. Endothelial Rho signaling is required for monocyte transendothelial migration. FEBS Lett. 517:261-266. [PubMed]. 425. Stubbs, M. T. 2002. Anthrax X-rayed: new opportunities for biodefence. Trends Pharmacol. Sci. 23:539-541. [PubMed]. 426. Stubbs, S., M. Rupnik, M. Gibert, J. Brazier, B. Duerden, and M. Popoff. 2000. Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol. Lett. 186:307-312. [PubMed]. 427. Sugai, M., T. Enomoto, K. Hashimoto, K. Matsumoto, Y. Matsuo, H. Ohgai, Y.-M. Hong, S. Inoue, K. Yoshikawa, and H. Suginaka. 1990. A novel epidermal cell differentiation inhibitor (EDIN): purification and characterization from Staphylococcus aureus. Biochem. Biophys. Res. Commun. 173:92-98. [PubMed]. 428. Sugii, S., and S. Kozaki. 1990. Hemagglutinating and binding properties of botulinum C2 toxin. Biochim. Biophys. Acta 1034:176-179. [PubMed]. 429. Suttorp, N., M. Polley, J. Seybold, H. Schnittler, W. Seeger, F. Grimminger, and K. Aktories. 1991. Adenosine diphosphate-ribosylation of G-actin by botulinum C2 toxin increases endothelial permeability in vitro. J. Clin. Investig. 87:1575-1584. [PubMed]. 430. Swartz, M. N. 2001. Recognition and management of anthrax—an update. N. Engl. J. Med. 345:1621-1626. [PubMed]. 431. Tabas, I., X. Zha, N. Beatini, J. N. Myers, and F. R. Maxfield. 1994. The actin cytoskeleton is important for the stimulation of cholesterol esterification by atherogenic lipoproteins in macrophages. J. Biol. Chem. 269:22547-22556. [PubMed]. 432. Takada, T., K. Iida, and J. Moss. 1995. Conservation of a common motif in enzymes catalyzing ADP-ribose transfer. J. Biol. Chem. 270:541-544. [PubMed]. 432a. Tan, Y., N. R. Hackett, J. L. Boyer, and R. G. Crystal. 2003. Protective immunity evoked against anthrax lethal toxin after a single intramuscular administration of an adenovirus-based vaccine encoding humanized protective antigen. Hum. Gene Ther. 14:1673-1682. [PubMed]. 433. Tang, G., and S. H. Leppla. 1999. Proteasome activity is required for anthrax lethal toxin to kill macrophages. Infect. Immun. 67:3055-3060. [PubMed]. 434. Tang, W. J., J. Krupinski, and A. G. Gilman. 1991. Expression and characterization of calmodulin-activated (type I) adenylylcyclase. J. Biol. Chem. 266:8595-8603. [PubMed]. 434a. Thelestam, M., E. Chaves-Olarte, M. Moos, and C. von Eichel-Streiber. 1999. Clostridial toxins acting on the cytoskeleton, p. 147-173. In J. E. Alouf and J. H. Freer (ed.), The comprehensive sourcebook of bacterial protein toxins. Academic Press, Inc., New York, N.Y. 435. Tonello, F., M. Seveso, O. Marin, M. Mock, and C. Montecucco. 2002. Screening inhibitors of anthrax lethal factor. Nature 418:386. [PubMed]. 436. Trachtman, P. 2002. Hero for our time. Smithsonian 2002:(Jan.):34-41. 437. Tsakiridis, T., A. Bergmann, R. Somwar, C. Taha, K. Aktories, T. F. Cruz, A. Klip, and G. P. Downey. 1998. Actin filaments facilitate insulin activation of the Src and collagen homologous/mitogen-activated protein kinase pathway leading to DNA synthesis and c-fos expression. J. Biol. Chem. 273:28322-28331. [PubMed]. 438. Tsuge, H., M. Nagahama, H. Nishimura, J. Hisatsune, Y. Sakaguchi, Y. Itogawa, N. Katunuma, and J. Sakurai. 2003. Crystal structure and site-directed mutagenesis of enzymatic components from Clostridium perfringens iota-toxin. J. Mol. Biol. 325:471-483. [PubMed]. 439. Turnbull, P. C. 2002. Introduction: anthrax history, disease and ecology. Curr. Top. Microbiol. Immunol. 271:1-19. [PubMed]. 440. Turnbull, P. C., M. G. Broster, J. A. Carman, R. J. Manchee, and J. Melling. 1986. Development of antibodies to protective antigen and lethal factor components of anthrax toxin in humans and guinea pigs and their relevance to protective immunity. Infect. Immun. 52:356-363. [PubMed]. 441. Uzal, F. A., J. J. Plumb, L. L. Blackall, and W. R. Kelly. 1997. PCR detection of Clostridium perfringens producing different toxins in faeces of goats. Lett. Appl. Microbiol. 25:339-344. [PubMed]. 442. Valderrama, F., J. M. Duran, T. Babia, H. Barth, J. Renau-Piqueras, and G. Egea. 2001. Actin microfilaments facilitate the retrograde transport from the Golgi complex to the endoplasmic reticulum in mammalian cells. Traffic 2:717-726. [PubMed]. 443. Valderrama, F., A. Luna, T. Babia, J. A. Martinez-Menarguez, J. Ballesta, H. Barth, C. Chaponnier, J. Renau-Piqueras, and G. Egea. 2000. The Golgi-associated COPI-coated buds and vesicles contain beta/gamma-actin. Proc. Natl. Acad. Sci. USA 97:1560-1565. [PubMed]. 444. van Damme, J., M. Jung, F. Hofmann, I. Just, J. Vandekerckhove, and K. Aktories. 1996. Analysis of the catalytic site of the actin ADP-ribosylating Clostridium perfringens iota toxin. FEBS Lett. 380:291-295. [PubMed]. 445. Vandekerckhove, J., B. Schering, M. Bärmann, and K. Aktories. 1987. Clostridium perfringens iota toxin ADP-ribosylates skeletal muscle actin in Arg-177. FEBS Lett. 225:48-52. [PubMed]. 446. Vandekerckhove, J., B. Schering, M. Bärmann, and K. Aktories. 1988. Botulinum C2 toxin ADP-ribosylates cytoplasmic β/γ-actin in arginine 177. J. Biol. Chem. 263:696-700. [PubMed]. 447. Van Ness, B. G., J. B. Howard, and J. W. Bodley. 1980. ADP-ribosylation of elongation factor 2 by diphtheria toxin. J. Biol. Chem. 255:10710-10716. [PubMed]. 448. Varughese, M., A. Chi, A. V. Teixeira, P. J. Nicholls, J. M. Keith, and S. H. Leppla. 1998. Internalization of a Bacillus anthracis protective antigen-c-Myc fusion protein mediated by cell surface anti-c-Myc antibodies. Mol. Med. 4:87-95. [PubMed]. 449. Varughese, M., A. V. Teixeira, S. Liu, and S. H. Leppla. 1999. Identification of a receptor-binding region within domain 4 of the protective antigen component of anthrax toxin. Infect. Immun. 67:1860-1865. [PubMed]. 450. Verschueren, H., I. Van der Taelen, J. Dewit, J. De Braekeleer, P. De Baetelier, K. Aktories, and I. Just. 1995. Effects of Clostridium botulinum C2 toxin and cytochalasin D on in vitro invasiveness, motility and F-actin content of a murine T-lymphoma cell line. Eur. J. Cell Biol. 66:335-341. [PubMed]. 451. Vischer, U. M., H. Barth, and C. B. Wollheim. 2000. Regulated von Willebrand factor secretion is associated with agonist-specific patterns of cytoskeletal remodeling in cultured endothelial cells. Arterioscler. Thromb. Vasc. Biol. 20:883-891. [PubMed]. 452. Vitale, G., L. Bernardi, G. Napolitani, M. Mock, and C. Montecucco. 2000. Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor. Biochem. J. 352:739-745. [PubMed]. 453. Vitale, G., R. Pellizzari, C. Recchi, G. Napolitani, M. Mock, and C. Montecucco. 1998. Anthrax lethal factor cleaves the N-terminus of MAPKKs and induces tyrosine/threonine phosphorylation of MAPKs in cultured macrophages. Biochem. Biophys. Res. Commun. 248:706-711. [PubMed]. 454. Viviani, B., C. L. Galli, and M. Marinovich. 1996. Is actin polymerization relevant to neurosecretion? A study on neuroblastoma cells. Biochem. Biophys. Res. Commun. 223:712-717. [PubMed]. 456. Wahl, S., H. Barth, T. Ciossek, K. Aktories, and B. K. Mueller. 2000. Ephrin-A5 induces collapse of growth cones by activating Rho and Rho kinase. J. Cell Biol. 149:263-270. [PubMed]. 457. Walker, P., I. Batty, and J. Egerton. 1979. The typing of C. perfringens and the veterinary background. Papua New Guinea Med. J. 22:50-56. 459. Watters, J. W., K. Dewar, J. Lehoczky, V. Boyartchuk, and W. F. Dietrich. 2001. Kif1C, a kinesin-like motor protein, mediates mouse macrophage resistance to anthrax lethal factor. Curr. Biol. 11:1503-1511. [PubMed]. 460. Webster, J. I., L. H. Tonelli, M. Moayeri, S. S. Simons, S. H. Leppla, and E. M. Sternberg. 2003. Anthrax lethal factor represses glucocorticoid and progesterone receptor activity. Proc. Natl. Aad. Sci. USA 100:5706-5711. 461. Wegner, A., and K. Aktories. 1988. ADP-ribosylated actin caps the barbed ends of actin filaments. J. Biol. Chem. 263:13739-13742. [PubMed]. 462. Wegner, A., K. Aktories, A. Ditsch, I. Just, B. Schoepper, N. Selve, and M. Wille. 1994. Actin-gelsolin interaction. Adv. Exp. Med. Biol. 358:97-104. [PubMed]. 463. Weigt, C., I. Just, A. Wegner, and K. Aktories. 1989. Nonmuscle actin ADP-ribosylated by botulinum C2 toxin caps actin filaments. FEBS Lett. 246:181-184. [PubMed]. 464. Weinstein, J. N., T. G. Myers, P. M. O'Connor, S. H. Friend, A. J. Fornace, Jr., K. W. Kohn, T. Fojo, S. E. Bates, L. V. Rubinstein, N. L. Anderson, et al. 1997. An information-intensive approach to the molecular pharmacology of cancer. Science 275:343-349. [PubMed]. 465. Welkos, S., A. Friedlander, S. Weeks, S. Little, and I. Mendelson. 2002. In vitro characterization of the phagocytosis and fate of anthrax spores in macrophages and the effects of anti-PA antibody. J. Med. Microbiol. 51:821-831. [PubMed]. 466. Welkos, S., S. Little, A. Friedlander, D. Fritz, and P. Fellows. 2001. The role of antibodies to Bacillus anthracis and anthrax toxin components in inhibiting the early stages of infection by anthrax spores. Microbiology 147:1677-1685. [PubMed]. 467. Welkos, S. L., J. R. Lowe, F. Eden-McCutchan, M. Vodkin, S. H. Leppla, and J. J. Schmidt. 1988. Sequence and analysis of the DNA encoding protective antigen of Bacillus anthracis. Gene 69:287-300. [PubMed]. 468. Wenzel-Seifert, K., H. Lentzen, K. Aktories, and R. Seifert. 1997. Complex regulation of human neutrophil activation by actin filaments: dihydrocytochalasin B and botulinum C2 toxin uncover the existence of multiple cation entry pathways. J. Leukoc. Biol. 61:703-711. [PubMed]. 469. Werner, G., H. Hagenmaier, H. Drautz, A. Baumgartner, and H. Zahner. 1984. Metabolic products of microorganisms. 224. Bafilomycins, a new group of macrolide antibiotics. Production, isolation, chemical structure and biological activity. J. Antibiot. 37:110-117. [PubMed]. 470. Wertman, K. F., and D. G. Drubin. 1992. Actin constitution: guaranteeing the right to assemble. Science 258:759-760. [PubMed]. 471. Wesche, J., J. L. Elliott, P. O. Falnes, S. Olsnes, and R. J. Collier. 1998. Characterization of membrane translocation by anthrax protective antigen. Biochemistry 37:15737-15746. [PubMed]. 472. Wex, C. B., G. Koch, and K. Aktories. 1997. Effects of Clostridium botulinum C2 toxin-induced depolymerisation of actin on degranulation of suspended and attached mast cells. Naunyn-Schmiedeberg's Arch. Pharmacol. 355:319-327. [PubMed]. 473. Whittaker, C. A., and R. O. Hynes. 2002. Distribution and evolution of von Willebrand/integrin A domains: widely dispersed domains with roles in cell adhesion and elsewhere. Mol. Biol. Cell 13:3369-3387. [PubMed]. 473a. Wild, M. A., H. Xin, T. Maruyama, M. J. Nolan, P. M. Calveley, J. D. Malone, M. R. Wallace, and K. S. Bowdish. 2003. Human antibodies from immunized donors are protective against anthrax toxin in vivo. Nat. Biotechnol. 21:1305-1306. [PubMed]. 474. Wilde, C., and K. Aktories. 2001. The Rho-ADP-ribosylating C3 exoenzyme from Clostridium botulinum and related C3-like transferases. Toxicon 39:1647-1660. [PubMed]. 475. Wilde, C., G. S. Chhatwal, G. Schmalzing, K. Aktories, and I. Just. 2001. A novel C3-like ADP-ribosyltransferase from Staphylococcus aureus modifying RhoE and Rnd3. J. Biol. Chem. 276:9537-9542. [PubMed]. 476. Wille, M., I. Just, A. Wegner, and K. Aktories. 1992. ADP-ribosylation of the gelsolin-actin complex by clostridial toxins. J. Biol. Chem. 267:50-55. [PubMed]. 477. Williams R. C., M. L. Rees, M. F. Jacobs, Z. Pragai, J. E. Thwaite, L. W. Baillie, P. T. Emmerson, and C. R. Harwood. 2003. Production of Bacillus anthracis protective antigen is dependent on the extracellular chaperone, PrsA. J. Biol. Chem. 278:18056-18062. [PubMed]. 478. Wright, G. G., T. W. Green, and R. G. Kanode, Jr. 1954. Immunizing activity of alum-precipitated protective antigen. J. Immunol. 73:387-391. [PubMed]. 479. Wright, G. G., and G. L. Mandell. 1986. Anthrax toxin blocks priming of neutrophils by lipopolysaccharide and by muramyl dipeptide. J. Exp. Med. 164:1700-1709. [PubMed]. 480. Yamagishi, T., K. Sugitani, K. Tanishima, and S. Nakamura. 1997. Polymerase chain reaction test for differentiation of five toxin types of Clostridium perfringens. Microbiol. Immunol. 41:295-299. [PubMed]. 481. Yamakawa, K., S. Nishida, and S. Nakamura. 1983. C2 toxicity in extract of Clostridium botulinum type C spores. Infect. Immun. 41:858-860. [PubMed]. 482. Yan, M., and R. J. Collier. 2003. Characterization of dominant-negative forms of anthrax protective antigen. Mol. Med. 9:46-51. [PubMed]. 483. Yonushonis, W. P., M. J. Roy, R. J. Carman, and R. E. Sims. 1987. Diagnosis of spontaneous Clostridium spiroforme iota enterotoxemia in a barrier rabbit breeding colony. Lab. Anim. Sci. 37:69-71. [PubMed]. 484. Yoo, H. S., S. U. Lee, K. Y. Park, and Y. H. Park. 1997. Molecular typing and epidemiological survey of prevalence of Clostridium perfringens types by multiplex PCR. J. Clin. Microbiol. 35:228-232. [PubMed]. 485. Zepeda, H., R. V. Considine, H. L. Smith, J. R. Sherwin, I. Ohishi, and L. L. Simpson. 1988. Actions of the Clostridium botulinum binary toxin on the structure and function of Y-1 adrenal cells. J. Pharmacol. Exp. Ther. 246:1183-1189. [PubMed]. 486. Zhang, Y., Y. Kida, K. Kuwano, Y. Misumi, Y. Ikehara, and S. Arai. 2001. Role of furin in delivery of a CTL epitope of an anthrax toxin-fusion protein. Microbiol. Immunol. 45:119-125. [PubMed]. 487. Zhao, J., J. C. Milne, and R. J. Collier. 1995. Effect of anthrax toxin's lethal factor on ion channels formed by the protective antigen. J. Biol. Chem. 270:18626-18630. [PubMed]. |